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ABSTRACT
Assessing the Proteolytic Virulence Factors of Staphylococcus aureus
Yue Cheng Zhu, 2011
Department of Microbiology and Immunology 
University of Western Ontario
Staphylococcus aureus is implicated in many different infections and is known to readily build 
biofilms on host tissues and biological implants, leading to numerous transplant and implant 
related complications every year. Its proteases, especially those encoded by the sspABC operon, 
may play a role in biofilm dispersal and are the focus of this study. A protease-deficient mutant 
of S. aureus was constructed through allelic replacement of the sspABC operon, and the resulting 
mutant was used to assess changes in vitro and in vivo through biofilm growth assays under 
various conditions of acid stress and carbon source supplementation, and in a murine 
bacteraemia model. Deletion of the proteases of sspABC operon led to increased thickness of 
biofilm mat and formation of large aggregations of bacterial communities. In the murine abscess 
model, deletion of proteases of the sspABC resulted in no significant differences in overall 
virulence despite possible differences in bacterial distribution.
Keywords: Staphylococcus aureus, protease-dependent biofilm dispersal, V8 serine protease, 
Staphopain B, murine abscess model
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CHAPTER 1: LITERATURE REVIEW
1.1. Significance of Staphylococcus aureus infections -  a history
First isolated in the 1880s, Staphylococcus aureus has represented a major source of 
morbidity, mortality, and financial burden to society on a world-wide scale (Ogston, 1882). Prior 
to the advent of antibiotics for hospital use, most notably penicillin in the 1940s, S. aureus 
bacteraemia was associated with poor prognosis and survival of patients, with a reported 
mortality rate of over 80% (Skinner and Keefer, 1941). Due to its ability to infect multiple 
tissues and utilize multiple points of entry, S. aureus infections manifest in a variety of forms, 
the most common of which are skin and soft-tissue infections. The hallmark of such infections is 
the pus-filled abscess, forming metastatic lesions in the fonn of boils, carbuncles, and infected 
skin vesicles. This mode of infection will be discussed in greater detail in this report. Other 
forms of soft-tissue infection include cellulitis and arteriosclerotic gangrene (Skinner and Keefer, 
1941). When taken in via the respiratory tract, S. aureus is able to infect and form peritonsillar 
abscesses as well as cause otitis media, sinusitis, and more serious conditions such as bacterial 
pneumonia. 5. aureus is also implicated in primary osteomyelitis and genito-urinary infections 
leading to puerperal sepsis and acute pyelonephritis. As a common cause of nosocomial 
endocarditis, cases caused by S. aureus result in higher rates of mortality than other pathogens 
(Fernandez-Guerrero et al, 2009). S. aureus produces an array of secreted toxins as well, 
including several enterotoxins and toxic shock syndrome toxin, the causative agent of toxic 
shock syndrome (Bohach et al, 1990). In conjunction with the wide variety of infectious diseases 
associated with S. aureus, it also displays high prevalence in the human population, with an 
average rate of 37% asymptomatic carriage of the bacterium in the general population at any 
point in time by persistent or transient earners in North America (Kluytmans et al, 1997).
Carriage of S. aureus has been implicated as a factor that places the carrier at higher risk of 
development of infections, most notably in surgical patients, patients undergoing dialysis, and 
other immunocompromised individuals (Kluytmans et al, 1997; Noble et al, 1967; Wenzel and 
Perl, 1995). Classically, populations at highest risk of S. aureus infections are those associated 
with the hospital setting, though community associated strains have been rapidly replacing 
hospital associated strains in recent years (Enright et al, 2002). Although treatment regimes have 
improved over the past few decades and most S. aureus infections are no longer associated with 
high mortality, it remains a leading cause of infectious morbidity in hospitals and the community, 
carrying between 2000 and 2001 an estimated annual cost of $14 billion for screening, treatment, 
and control in the United States alone (Noskin et al, 2005). - __
1.2. Description of Staphylococcus aureus
S. aureus belongs to the taxonomic family Micrococcaceae, along with other species of 
staphylococci and micrococci (Witte et al, 2006). In appearance, they are Gram positive, non- 
motile, spherical cocci that divide along all three perpendicular planes to generate characteristic 
irregular grape-like clusters (Ogston, 1882; Tzagalogg and Novick, 1977), for which the genus is 
named. The species is named for the golden or orange carotenoid pigment, staphyloxanthin, 
which is produced by most strains of the bacteria when they are grown in vitro on plate agar 
(Pelz et al, 2005).
As S. aureus represents the most significant human pathogen within the Staphylococcus 
genus, several biochemical or metabolic tests have been established for routine use in species 
identification. These tests capitalize on the production of coagulase, the activity of which 
activates the serine protease precursor prothrombin and results in the formation of a fibrin clot
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(Boden and Flock, 1989), the presence of bacterial cell-surface associated clumping factor, a 
protein which will directly bind fibrinogen and cause agglutination in human blood plasma 
(McDevitt et al, 1992; Moreillon et al, 1995), and finally the production of the catalase enzyme, 
which is produced by all staphylococci and will rapidly decompose hydrogen peroxide to oxygen 
and water (Mandell, 1975). Other supplementary selective and differential tests include the use 
of mannitol salt agar, the high salt content of which inhibits growth of most bacteria belonging to 
genera other than Micrococcaceae, while fermentation of mannitol to acidic fennentation 
products that can be observed through an included pH indicator is used for presumptive 
identification of S. aureus (Leboffe and Pierce, 2008).
1.3. Commensal colonization
Along with the infections in which it is implicated, S. aureus can also be found 
colonizing human hosts without overt detrimental effects (Casewrell and Hill, 1986). It can be 
isolated from most areas of the host body, but most commonly in the anterior nares. This is 
thought to be the primary reservoir, as elimination of nasally colonized bacteria often results in 
elimination of bacteria from other areas of the host. Human hosts colonized by S. aureus can be 
divided into three broad groups: persistent carriers, representing 20% of the total population; 
intermittent carriers, representing 60% of the population; and the remaining 20% are non-carriers. 
Persistent carriers are colonized by and almost always retain the same strain of S. aureus, and 
this carriage status appears to offer protection from acquisition of a different strain of S. aureus 
when the host is not undergoing antibiotic treatment. This protection is not present in intermittent 
carriers, who will be re-colonized by varying strains over time (Noble et al, 1965). Though 
colonization is implicated as a risk factor for the development of S. aureus infections, surveys
3
have indicated that there may be no correlation between colonization and serious skin infections 
in the community (Miller et al, 2009).
4
There are multiple factors that influence the likelihood of a human host to be colonized 
by S. aureus. Children are more likely to be persistent carriers, and their carrier status often 
changes between the ages of 10 and 20. Significantly increased carriage rates are also reported to 
occur in hosts with nasal injuries, intravenous drug addictions, S. aureus skin infections, atopic 
dermatitis (Breuer et al, 2002), or those with immune-deficiencies such as insulin-dependent 
diabetes mellitus, human immunodeficiency virus (HIV) infections, or patients of invasive 
procedures such as dialysis (Wenzel and Perl, 1995).
In its primary site of colonization, the nares, S. aureus must be able to adhere tightly to 
the surfaces presented. The nostril contains hairs, sebaceous glands, and sweat glands, the 
secretions of which possess antimicrobial effects that do not present a barrier to S. aureus 
colonization. To adhere, the bacteria may rely on physiochemical forces such as hydrophobic 
interactions. Alternatively, the bacteria may bind through the activity of bacterial surface 
proteins that interact specifically with host cell receptors (Brouillette et al, 2003; O’Brien et al, 
2002). During colonization, toxin production is reduced while surface proteins are upregulated 
(Burian et al, 2010). These proteins include adhesins and fibronectin binding proteins, members 
of the family of staphylococcal virulence factors named the microbial surface components 
recognizing adhesive matrix molecules (MSCRAMMs), which will be discussed in further detail.
1.4. History of antibiotic resistance
Penicillin was introduced for the treatment of S. aureus infections in 1940, and within 
two years, a strain of penicillin resistant S. aureus was isolated in a hospital. By 1960, 80% of S.
aureus strains were resistant to penicillin. Currently, fewer than 5% of S. aureus strains remain 
sensitive to penicillin (Deurenberg and Stobberingh, 2008; Enright et al, 2002). Methicillin, a 
second-generation beta-lactam antibiotic that is resistant to degradation by beta-lactamase 
enzyme, was introduced in 1959 for use with penicillin-resistant strains of the bacteria. 
Methicillin resistant strains of S. aureus (MRSA) were first isolated in 1961, in which resistance 
is conferred by a modified penicillin binding protein encoded by the mecA gene. mecA is located 
within a mobile genetic island named the staphylococcal cassette chromosome mee (SCCmec) 
thought to originate from the coagulase negative Staphylococcus haemolyticus (Ito et al, 2003). 
SCC mec is organized in five domains, beginning with a region of “junkyard" DNA named the J1 
region, followed by the mecA gene, the J2 region, the cassette chromosome recombinase (ccr) 
gene complex, and finally the J3 region. The “junk” regions appear to exert no effect on 
methicillin resistance of the bacteria. There are currently potentially eight allotypes of SCC mec 
(Zhang et al, 2009), the majority of which confer only beta-lactam antibiotic resistance, but types 
II and III also contain elements that were acquired through horizontal gene transfer and variously 
confer resistance to other aminoglycoside, macrolide, and heavy metal antibiotics. The allotypes 
are categorized by the type of the two defining ORFs, mec and ccr, the latter of which is 
responsible for the mobility of the SCC mec (Hiramatsu et al, 2001; Olivieri et al, 2001; Oliviera 
et al, 2002). Currently, the glycopeptide vancomycin is the antibiotic of choice for treatment of 
MRSA, though vancomycin intermediate and resistant strains of S. aureus have been isolated in 
past years. In S. aureus, vancomycin resistance is acquired through multiple strategies 
(Yamakawa et al, 2011), but the most common is through mutation of the vraSR cell wall stress 
response system (Belcheva et al, 2011) that results in the accumulation of excess cell wall 
peptidoglycan (Cui et al, 2000).
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Strains of MRS A can be further categorized into hospital associated (HA-) and 
community associated (CA-), where CA-MRSA are noted for their increased virulence and 
ability to infect otherwise healthy individuals. CA-MRSA-10, or USA300 (Miller et al, 2005), is 
epidemic within North America and presents the largest challenge to public health, alongside the 
CA-MRSA USA400 (McDougal et al, 2003). USA300 is of particular interest due to its 
prevalence as an epidemic in the United States, and to its heightened production of virulence 
factors (Witte et al, 2007), so much that it is termed a hypervirulent strain (Haque et al, 2007; 
Shaw et al, 2004; Gordon and Lowy, 2008). USA300 possesses type IV SCCmec, and in general, 
CA-MRSA possess SCC mec types IV or V (Zhang et al, 2008). These are shorter elements, 24- 
28 Kb in size, that do not contain additional antibiotic resistance genes acquired as mobile 
genetic elements, whereas HA-MRSA strains often possess SCC mec types II or III (IWG-SCC, 
2009).
1.5. The Staphylococcus aureus genome
The S. aureus genome is composed of a circular chromosome of approximately 2.8 Mb in 
size, encoding -2900 ORFs, of which 75% represents the core genome. The variability between 
strains is attributable mainly to mobile genetic elements including pathogenicity islands, 
transposons, bacteriophages, and other insertion sequences (Gillaspy et al, 2006; Malachowa and 
Deleo, 2010). These mobile genetic elements include SCCmec, and two elements found 
exclusively or first discovered in USA300: staphylococcal pathogenicity island SaPI5, which 
encodes two enterotoxin superantigens, and the arginine catabolic mobile element (ACME), a 
metabolic element most likely acquired from Staphylococcus epidermidis that contributes to 
enhanced ability to survive in hosts (Miragaia et al, 2009).
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Strains will also variously carry extra-chromosomal elements that most commonly confer 
resistance to antimicrobial agents. USA300, for example, contains at least one endogenous 27-37 
Kb plasmid, pUSA03, which encodes resistance to one or more heavy metals including cadmium 
ions (Cd2+), and to various antibiotics including macrolides (erythromycin), lincosamides 
(clindamycin), aminoglycosides (kanamycin, neomycin), bacitracin, and others (Diep et al,
2006). Clonal subtypes may also possess smaller plasmids, including pUSAOl, of cryptic 
function, and pUSA02, which confers tetracycline resistance and is 99.9% identical to an 
antibiotic resistance plasmid found in S. epidermidis (Kennedy et al, 2010).
1.6. Genotyping of Staphylococcus aureus —_
Outbreaks of S. aureus infections may often coincide with emergence of epidemic clones, 
through clonal expansion of pre-existing strains. It is therefore of interest to characterize the 
emergent clones in order to differentiate them from non-epidemic strains. There are various 
methods of typing S. aureus strains, ranging from phenotypic serotyping for differentiation 
through antigen presence, to genetic methods such as DNA fingerprinting through pulse-field gel 
electrophoresis (PFGE) (Tenover et al, 1995) and Multilocus Sequence Typing (MLST), the 
latter of which has proven to be a preferred method of S. aureus typing due to its unambiguity 
(Witte et al, 2006). MLST relies on the analysis of internal fragments of the sequences of seven 
housekeeping genes considered to be under neutral selective pressure, and strains are categorized 
based on which of multiple possible alleles are present at each of the seven loci. All strains that 
differ at no more than two of the seven loci are assigned to a clonal complex that is named based 
on the sequence type of the clonal ancestor. Thus. MLST is able to distinguish major clusters of 
related lineages in the molecular evolution of S. aureus (Enright et al, 2000).
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MLST is not sufficient for differentiation between strains of a single clonal complex or 
analysis of infection outbreaks, in which single nucleotide polymorphisms (SNPs) are more 
likely responsible for the emergent variance than allelic recombination. For these purposes, a 
method of typing based on the staphylococcal Protein A {spa) locus of S. aureus was developed 
(Koreen et al, 2004. Frenay et al, .1996). The locus contains an “X region” that encodes variable 
numbers of 24 bp repeats, of which a number of distinct sequences exist, and the region is prone 
to spontaneous mutations as well as gain or loss of repeats through slip-strand mispairing (van 
Belkum, 1999). Strains are therefore typed according to the combination of X region repeats they 
possess. While this method provides finer discrimination than PFGE or MLST when used to 
distinguish members of a single clonal complex, it is unable to distinguish between members of 
distinct clonal complexes that possess common X region analyses, and it is a combination of the 
three methods that results in the most accurate typing (Strommenger et al, 2006).
Together with SCCmec typing, these molecular typing methods result in a precise and 
unambiguous description of extant strains of S. aureus. For example, epidemic strain USA300 is 
designated USA300-ST-8-spa-t008-MRSA-IVa, which indicates that it falls under pulse field 
pattern USA300, sequence type (ST) 8, and it is a representative member of clonal complex 8 
(CC8). It is categorized as spa type t008, and SCC mec type IVa. The other common CA-MRSA 
strain in the United States is designated USA400-ST-l-5pa-tl28-MRSA-IVa (Moran et al, 2006; 
Zhang et al, 2009) and is a member of CC1. In atopic dermatitis patients, who will commonly be 
colonized and infected by S. aureus, CC1 strains have been associated with increased virulence 
over strains of other CCs, including CC8 and CC30. CC30 is of interest because it accounts for a 
large proportion of nasal carriage (Ko et al, 2008), though this difference is minimal when
9
compared to other CCs (Yeung et al, 2010). This provides insight into the evolutionary relations 
and epidemiology of important epidemic strains in North America.
1.7. Cell surface virulence
The cell wall of S. aureus is composed of 50% peptidoglycan, which consists of a 
polymer of alternating Wacetylmuramic acid (NAM) and iV-acetylglucosamine (NAG) 
(Strominger et al, 1959). As with other Gram positive organisms, lipoteichoic acid is a second 
major component. Eleven capsular serotypes have been identified, of which type 5 and 8 account 
for the majority of MRSA infections and are found to be antiphagocytic (Thakker et al, 1998). 
While 90% of clinical isolates are encapsulated, clinical strains either produce microcapsules or, 
in the case of the CA-MRSA USA300, no capsule at all (Montgomery et al, 2008). Work with a 
capsule-positive strain of S. aureus, Reynolds, has indicated that the presence of the capsule 
enhances both nasal colonization (Kiser et al, 1999) in a murine nasal model and reduces 
phagocytosis in a murine bacteraemia model (Thakker et al, 1998).
S. aureus produces a variety of cell-surface anchored proteins that allow the bacteria to 
bind to components of the host’s extracellular matrix (ECM) using specific binding sites (Walsh 
et al, 2008). These proteins, with the exception of an elastin-binding protein (EbpS) (Park et al, 
1996; Downer et al, 2001), belong to the MSCRAMM family of virulence factors and are 
covalently linked to cell wall peptidoglycan. The MSCRAMM family play important roles in 
immune evasion and biofilm formation, as will be discussed in following sections. These 
anchored proteins possess a long N-terminal signal peptide required for Sec secretion system- 
dependent protein secretion and a C-terminal cell-wall spanning domain that contains an LPXTG 
motif, a hydrophobic domain, and a tail of positively charged residues. The signal peptide is
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cleaved by a signal peptidase prior to secretion, and the LPXTG motif is cleaved between the 
threonine and glycine residues prior to the covalent linkage of the threonine to a side chain of S. 
aureus peptidoglycan by the transpeptidase sortase A (Schneewind et al, 1995). Several 
MSCRAMMs have been isolated and characterized, including the prototypic representative, 
Protein A, first discovered for its ability to bind immunoglobulin G (IgG). Protein A has since 
been found to bind von Willebrand factor, a human blood glycoprotein involved in coagulation 
(Hartlieb et al, 2000), and so may play a role in mediation of S. aureus attachment to sites of 
blood vessel endothelium damage.
Another important class of MSCRAMM is that of the fibronectin binding proteins 
(FnBPs). S. aureus produces two related fibronectin binding proteins, FnBPA and FnBPB 
(Jonsson et al, 1991), and most strains will express both in tandem. As their name suggests, these 
proteins mediate bacterial binding to fibronectin, an ECM glycoprotein that itself binds 
components of the ECM and host cell surface integrins to play a large role in cell adhesion and 
wound healing. FnBP possesses a ligand binding domain that consists of several repeats 
approximately 40 aa in length, and this domain binds to the N-tenninus of fibronectin, which 
also consists of a series of repeated motifs (Signas et al, 1989). The presence of the repeats 
allows the FnBP to adhere to fibronectin tightly through the construction of a zipper-like 
secondary structure that is not apparent in the bacterial protein prior to binding of fibronectin 
(Ingham et al, 2004). FnBPA also binds and aggregates platelets, which may result in thrombosis 
(Heilmann et al, 2004).
The ability of S', aureus to coagulate blood is due in part to another family of 
MSCRAMMs that bind fibrinogen. It currently holds two structurally similar but unrelated 
proteins, clumping factor A (ClfA) and B (ClfB), that bind different domains of the host ligand
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fibrinogen in a manner regulated by Ca" concentration. At wound sites, where aggregation of 
fibrinogen and platelets would occur, Ca" concentration decreases compared to normal serum 
concentrations, thereby de-repressing fibrinogen-Clf interactions and allowing the bacteria to 
accumulate at these sites (O’Connell et al, 1998). Virulence was also significantly attenuated in a 
septic arthritis mouse model when fibrinogen was depleted prior to infection with ClfA- 
producing bacteria, indicating that Clf may mediate virulence through other mechanisms as well 
(Palmqvist et al, 2004).
1.8. Exotoxins
S. aureus produces a variety of secreted toxins that are responsible for. the majority of its 
pathogenesis and the majority of the in vivo phenotypes seen in this study. These toxins fall into 
three categories: the membrane active cytolytic toxins, the pyrogenic toxin superantigens, and 
the exfoliative toxins (Bohach, 2006; Dinges et al, 2000).
S. aureus cytotoxins include the highly potent a-haemolysin or a-toxin (Hla), which is 
secreted as a 293-residue monomer. Once bound to receptor sites, the monomers oligomerize as 
either hexamers or heptamers at the cell membrane surface in order to form a ring-shaped pore. 
The crystal structure of the pore is mushroom-shaped, and the lower channel is composed of an 
anti-parallel (3-barrel that is able to penetrate the cell’s lipid bilayer (Valeva et al, 1996). Upon 
formation of the channel, cell death may result directly from loss of osmotic homeostasis, influx 
or efflux of cations and other small molecules, necrosis, or apoptosis (Bhakdi and Tranum- 
Jensen, 1991; Essmann et al, 2003). Indirectly, Hla induces pro-inflammatory cytokines 
interleukin-la (IL-la) and IL-6, resulting in vasoaction and other inflammatory effects 
(Onogawa, 2006). Hla is responsible for bacterial survival post phagocytosis, and promotion of
1+
phagocyte lysis and subsequent release of internalized S. aureus (Bramley et al, 1989), a 
component of the various methods of immune evasion that will be discussed in further detail.
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S. aureus P-toxin is a phospholipase that disrupts cell membranes through the hydrolysis 
of sphingomyelin. Uniquely, its action takes place in two stages, the first being sphingomyelin 
hydrolysis at physiological temperatures of around 37°C, and the second being physical 
disruption of the membrane that takes place at lower temperatures of around 4°C (Aarestrup et al, 
2009). While P-toxin is implicated in tissue damage, a-toxin remains the major virulence factor 
in infection (O’Callaghan et al, 1997).
Other membrane active exotoxins include 5-toxin, a small helical protein that is thought 
to release membrane bound contents of target cells through accumulation of tQxin monomers that 
penetrate the membrane (Mellor et al, 1988; Bhakoo et al, 1982). The transcript of this toxin is 
involved in temporal control of the S. aureus growth pattern (Somerville et al, 2003), as will be 
discussed later. As well, this category includes bi-component toxins, of which y-toxin and 
Panton-Valentine Leukocidin (PVL) are the best characterized examples.
These bi-component toxins contain two complementary proteins that act synergistically 
to form oligomeric pores (Panton and Valentine, 1932). The two toxin subunits are designated S 
and F based on their slow or fast mobility seen in ion-exchange chromatography. PVL is of 
particular interest, because while it is not present in the vast majority of clinical isolates, it is 
found in many strains of CA-MRSA. PVL is implicated in several of the severe clinical 
symptoms of MRS A infections (Boyle-Vavra and Daum, 2007; Genestier et al, 2005), but its 
overall role as a determinant of pathogenicity is ambiguous due to conflicting virulence data
(Campo et al, 2011).
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The pyrogenic toxin superantigen set of virulence factors include the staphylococcal 
enterotoxins (SEs) and the toxic shock syndrome toxin-1 (TSST-1) (Schlievert et al, 1981). 
Superantigens (SAgs) bind to major histocompatibility complex class-II (MHC-II) molecules on 
antigen-presenting cells of the host at a distinct region of the molecule that is not responsible for 
peptide-antigen binding, and they then interact with and stimulate activation and proliferation of 
T-lymphocytes based on recognition of the Vp elements of the T-cell receptor (Jardetsky et al, 
1994). This results in non-antigen specific activation of T-cells, allowing up to 30% of the host’s 
T-cells to become activated and generating a cytokine storm composed mainly of IL-1, IL-2, 
tumour necrosis factor (TNF) a and p, and interferon-y. These and secondary proinflammatory 
molecules can result in acute systemic shock, fever, and immunosuppression (Lappin and 
Ferguson, 2009). The SEs and not TSST-1 are also implicated in staphylococcal food poisoning, 
where they are thought to stimulate mast cells and indirectly affect the emetic reflex centre 
(Holmberg and Blake, 1984).
Exfoliative toxins (ETs), of which there are several forms A to D in S. aureus alone, are 
serine proteases that have been found to be the causative agents of staphylococcal scalded-skin 
syndrome. The ETs degrade a desmosomal molecule in the skin that mediates cell-to-cell 
adhesion, resulting in sterile skin lesions and potential wide-spread peeling of skin strata (Rago 
et al, 2000). ETA has also been found to stimulate T-cells with Vp2 chains, much like the 
staphylococcal superantigens (Monday et al, 1999).
1.9. Exoenzymes
S. aureus produces a host of extracellular enzymes, most of which comprise direct or 
indirect virulence factors. Among these enzymes are proteins also identified as toxins, such as
the ETs and beta-hemolysin, enzymes important for bacterial metabolism and nutrition, and 
enzymes involved in immune evasion or direct virulence through the degradation of host 
molecules. The third category overlaps with the fourth, enzymes that specifically mediate 
extracellular proteolytic activity and whose attenuation resulted in a decrease in virulence in a 
mouse abscess model (Shaw et al, 2004), the staphylococcal proteases. This last category will be 
the focus of this work. There are three classes of proteases characterized in S. aureus, the 
metalloprotease, the serine protease, and the cysteine or thiol protease. All clinical isolates of S. 
aureus encode genes for one metalloprotease, aureolysin, one serine protease, the staphylococcal 
serine protease (SspA) or V8 protease, named for the strain in which it was first isolated 
(Cannona and Gray, 1987), and two cysteine proteases, staphopain A and staphopain B. 
Structural comparisons of staphopains A and B are shown in Fig. 1-A.
These exoenzymes are secreted as inactive zymogens with little or no activity, requiring 
proteolytic processing for activation. Staphopain A (ScpA) is encoded in the operon scp AB, 
where it is coexpressed with a cognate activation inhibitor, staphostatin A (ScpB). proScpA 
possesses a propeptide that immediately follows its N-terminal signal peptide, and the propeptide 
domain must be cleaved prior to protease activity. The zymogen rapidly autocatalyzes to release 
the propeptide domain in a sequential manner that generates multiple activation intermediates, 
cleaving preferentially at sites that possess a bulky or aromatic residue at the P2 subsite, and less 
specificity, but often a Thr or Lys at the PI subsite (Kalinska et al, 2011; Nickerson et al, 2010). 
While ScpA is secreted, ScpB is a cytoplasmic protein, optimized to capture an 
activation/folding intermediate of ScpA (Filipek et al, 2003) by binding in a substrate-like 
manner and likely binds to the first intermediate that does not present active site blocking or 
hindrance (Nickerson et al, 2010). Like other members of the papain family of proteases, ScpA
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Figure 1. Exoenzymes of S. aureus.
A) Structural comparison of staphopain A and staphopain B of S', aureus as shown in ribbon 
diagram form. In the left panel, the mature SspB domain is dark blue, and the propeptide is red, 
except for the magenta segment spanning the C-terminus of the propeptide, and the catalytic 
Cys243 and His34o are coloured green. The right panel shows a model proScpA structure (ScpA 
domain is light blue and the propeptide domain is yellow) superimposed on proSspB, again 
shaded in dark blue and red. Image taken from Nickerson et al, 2010.
B) Proteolytic activation steps of the Staphylococcal Proteolytic Cascade are shown. In the 
diagrams of aureolysin and SspA, the a helices are shown in red, the p strands in green, and the 
loops are in yellow. For aureolysin, the calcium ions are represented by brown spheres and the 




displays broad substrate specificity, with high activity against elastin, and is a potent inducer of 
vascular leakage through processing of kininogens to release bradykinin (Imamura et al, 2005; 
Mattsson et al, 2001), a peptide that functions to induce vasodilation, vascular permeability, and 
inflammation upon its binding to epithelial receptors. The remaining proteases of S. aureus are 
activated in a step-wise cascade, named the Staphylococcal Proteolytic Cascade (SPC), which 
will be discussed in further detail in the next section.
Other S. aureus exoenzymes, responsible for metabolic or pathogenic functions, include 
lipase, a term that encompasses both glycerol ester hydrolase, which degrades long chain 
insoluble triacylglycerols, and esterases, w'hich degrade short-chain water-soluble glycerol esters. 
These lipases are secreted as large proenzymes that possess the same enzymatic activity as the 
mature forms (Nokoleit et al, 1995; Rollof and Normark, 1992), and they are thought to possess 
a nutritional function, or they may play a role in virulence by releasing long-chain fatty acids that 
are known to impair immune function (Rollof et al, 1988). The same long-chain fatty acids are 
also bactericidal, and S. aureus is noted for its ability to inactivate these fatty acids through their 
esterification to cholesterol and other alcohols. This is accomplished through the action of the 
exoenzyme fatty-acid modifying enzyme (FAME), which has been identified phenotypically in 
most strains that produce lipase, though the genes encoding the enzyme remain elusive (Kapral 
et al, 1992).
In addition to |3-hemolysin, S. aureus produces a second phospholipase C (PLC). PLC 
shows phosphatidylinositol specificity and can degrade, in an RNaseA-like manner (Kravchuk 
2001), eukaryotic membrane inositol phospholipids that anchor a variety of surface proteins 
including receptors and adhesion molecules (Marques et al, 1989). S. aureus also produces two 
genetically distinct thermostable nucleases noted for their ability to spontaneously refold after
thermal unfolding (Tang et al, 2008). The nucleases hydrolyze both single and double stranded 
nucleic acids. Lastly, S. aureus produces hyaluronate lyase, a virulence enzyme important for its 
ability to hydrolyze hyaluronic acid, a linear polysaccharide and a major structural component of 
vertebrate ECM (Makris et al, 2004).
1.10. The Staphylococcal Proteolytic Cascade
The SPC is a stepwise proteolytic activation cascade involved in the activation of three 
different proteases of S. aureus, aureolysin, staphylococcal serine protease A (SspA), and 
staphopain B (SspB). The SPC is shown in Fig. 1-B. Aureolysin is an M4 class metalloprotease 
that requires histidine-mediated coordination of a zinc ion for activity. Like other 
metalloproteases such as thermolysin, to which aureolysin is structurally similar, the 
staphylococcal enzyme shows broad substrate specificity, preferentially cleaving at sites that 
possess a hydrophobic residue at the PI position (Beaufort et al, 2008, Supuran et al, 2002) in 
human substrates. Due to its broad specificity, autocatalytic activation of aureolysin is rapid and 
occurs at the TL86 and SV90 sites of its N-terminal propeptide (NTP). Like other M4 
metalloproteases, the NTP contains a broadly conserved fungalysin-thermolysin-propeptide (FTP) 
domain that is crucial for activation, but unlike other metalloproteases, the NTP is not inhibitory, 
but serves a stabilization function (Nickerson et al, 2008). Aureolysin is expressed maximally in 
mid-exponential growth and has been found to degrade fibrin (Sieprawska-Lupa et al, 2004) and 
Cathelicidin LL-37, and conversely is inducible by human antimicrobial peptides (Lai et al,
2007). It inactivates cell surface ClfB of S. aureus (McAleese et al, 2001), and has recently been 
characterized as able to degrade complement C3 (Larmaan et al, 2011). Aureolysin is required
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for the activation of mature SspA, where it must remove three final residues of the NTP at the 
NV69 processing site in the rate-limiting step.
SspA is encoded by the sspABC operon, in conjunction with SspB and staphostatin B 
(SspC). It is a glutamyl endopeptidase that possesses many similarities to trypsin, including the 
His-Ser-Asp catalytic triad and the multi-step activation that proceeds through several 
intermediates. After its N-terminal signal peptide, SspA possesses a glutamine-rich propeptide 
region that is processed autocatalytically at residues Gln43, Gln47, and Gln53, indicating that 
secondary structure is present in the zymogen and sufficient for autocatalysis. This self­
processing is necessary for optimal processing of the final three-amino acid propeptide region by 
aureolysin to release the mature enzyme, which degrades cell surface FnBR (MeGavin et al,
1997) and protein A (Karlsson et al, 2001). The presence of the final three residues completely 
blocks function, likely through steric hindrance of the active site (Nickerson et al, 2007). SspA is 
necessary for the catalytic activation of SspB, which represents the endpoint of the SPC.
SspB is the second staphopain produced by S. aureus, and like ScpA, it is encoded in an 
operon with its cognate inhibitor SspC. The two staphopains have likely evolved through 
paralogous ancestry, given their highly similar structures, but SspB possesses much narrower 
substrate specificity and has a high preference for Arg in the PI site (Massimi et al, 2002, 
Kalinska et al, 2011), such that it will not autocatalytically activate and does not show activity 
against elastin fibres. For this reason, SspC is not necessary as an inhibitor, and its mutation is 
not deleterious to the bacteria, indicating that it possesses diminished or altered function. The 
two staphostatins will not cross-react to inhibit their non-respective staphopains (Filipek et al,
2005).
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SspB distinguishes the pathogenic S. aureus from the commensal S. epidermidis, which 
encodes equivalents of aureolysin, staphopain A, and V8 protease, but does not possess 
staphopain B. This suggests that the second staphopain arose after evolutionary divergence of the 
two closely related species and its contribution is a compelling explanation for the increased 
virulence of S. aureus. SspB mimics the activity of plasma serine proteases such as plasmin, 
plasminogen activator, and kallikrein by selectively cleaving fibrinogen, fibronectin, and 
kininogen, resulting in vasodilation and vascular leakage. Its effects are less dramatic than those 
of ScpA, though the two proteases compound to induce a greater effect than either alone. SspB 
also possesses potent activity against other components of human ECM including collagen 
(Ohbayashi et al, 2010), and chemokines such as chemerin (Kulig et al, 2007).
It is the potential contribution of the SPC as a switch from the colonization mode of 
infection to invasive virulence through the previously mentioned degradation of adhesion factors 
and host tissues in order to allow metastatic spread, as well as the potential contribution to 
biofilm regulation, that will be the focus of this work.
1.11. Immune evasion
Integral to the S. aureus virulence strategy is a multitude of means to evade the innate 
immune system, of which a selection will be briefly described.
One of the best characterized immune evasion molecules is the chemotaxis inhibition 
protein of staphylococci (CHIPS), which competitively inhibits native agonist binding to the 
complement factor C5a receptor and the pathogen associated molecular pattern (PAMP) formyl 
peptides receptor (FPR) that neutrophils express (de Haas et al, 2004), thereby preventing 
neutrophil localization to the site of infection.
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S. aureus also inhibits the complement system in several other ways, including the highly 
effective staphylococcal complement inhibitor (SCIN), which binds to both C4bC2a and C3bBb 
C3 convertases to trap them in an inactive state, preventing the activity of C4bC2a mediated 
classical and lectin pathways as well as the C3bBb mediated alternative complement pathway 
(Garcia et al, 2010). Aureolysin has recently been found to take a more direct approach to 
complement inhibition through proteolytic cleavage of C3 (Laarman et al, 2011).
The extracellular adhesion protein (Eap) or MHC analog protein (Map) serves a dual 
function, both mediating bacterial attachment to intracellular adhesion molecule 1 (ICAM-1) 
expressed on the surfaces of epithelial cells (McGavin et al, 1993), and at the same time 
competitively blocking leukocyte localization, which depends upon beta-integrin and urokinase 
receptor recognition of the same ICAM-1 ligand (Chavakis et al, 2002. Haggar et al, 2004).
Most clinical isolates of S. aureus produce a bacterial capsule that can also inhibit 
opsonisation, but this capsule is minimal or absent in hypervirulent strains, where it is not 
necessary in light of other opsonisation inhibition mechanisms, including degradation of C3b and 
IgG by plasmin activated by staphylokinase, protein A binding of IgG, inhibition of opsonin 
deposition through ClfA mediated coating of bacteria with fibrinogen, and binding of secreted 
fibrinogen-binding protein (Clf) to C3 in order to block its deposition on the bacterial cell 
surface (Hair et al, 2008).
After S. aureus is phagocytosed, it may survive in or escape the phagolysosome, mainly 
through the secretion of the previously described Hla and the various extracellular proteases, 
which were found to be rapidly upregulated upon phagosomal uptake (Burlak et al, 2007). Hla 
can result in the direct escape of the bacteria from the phagosome through its pore-forming 
function, or it may alter the concentration gradient of the phagolysosome, in which acidification
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is a major method of bacterial killing. The proteases have been found to degrade the 
antimicrobial peptide (AMP) dermcidin, and may have activity against other AMPs secreted into 
the interior of the phagolysosome by granulocytes (Lai et al, 2007). In particular, aureolysin has 
been found to cleave the human AMP Cathelicidin LL-37 (Sieprawska-Lupa et. al., 2004). The 
muramidase lysozyme produced in phagolysosomes is ineffective against S. aureus due to 
acetylation of the bacterial peptidoglycan (Bera et al, 2004). S. aureus also possesses innate 
resistance to killing through oxidative burst by the actions of both the superoxide dismutases it 
encodes (Karavolos et al, 2003) and its staphyloxanthin pigment, which is able to scavenge free 
oxygen radicals (Liu et al, 2005).
As described in the section on exotoxins, S. aureus also produces several toxins that 
directly kill leukocytes through the same pore-forming mechanism as haemolytic a-toxin, 
including the two component exotoxins PVL and y-toxin.
1.12. Regulation of virulence factors
The success of the S. aureus virulence strategy of rapid switching between colonization 
and invasion phases of infection is largely due to tight control of its virulence expression through 
several interconnected systems of regulation.
The best characterized system is that of accessory gene regulation (agr), a locus that 
encodes both a two component system (TCS) and an effector molecule RNAIII under the control 
of distinct P2 and P3 promoters (Recsei et al, 1986). The P2 promoter drives expression of the 
agrBDCA operon, where the RNAII transcript encodes the histidine kinase receptor and specific 
response regulator of its TCS and its activating ligand, autoinducing peptide (AIP). As a quorum 
sensing system, its overall function is to sense bacterial cell density (Novick, 2003). AIP is
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encoded by agrD, and it undergoes post-transiational modification prior to secretion by the 
transmembrane AgrB protein. AIP binds to the TCS receptor AgrC on its N-terminal 
transmembrane domain, and this induces the activity of response regulator AgrA, which binds to 
and upregulates both P2 and P3 promoters in a positive feedback loop. The P3 transcript encodes 
8-toxin, but it is the transcript itself that functions as both a translational regulator o f HLA, 
which it derepresses, and Protein A, which it inhibits, and as a transcriptional regulator of several 
other regulatory systems. The secondary structure of RNAIII is crucial for transcriptional 
regulation of exoprotein synthesis that occurs through the action of intermediary regulatory 
proteins (Novick et al, 2003), but for its secondary translational activation function, it is likely 
that the transcript must unfold in order to allow the conformational change that results in 
translation of 5-toxin, and the base-pairing that alters hla mRNA conformation and derepression 
(Novick, 2006). Deletions or mutations to RNAIII all alter the expression levels of several 
exoproteins (Novick et al, 2003), and a nonsynonymous mutation found in AgrC in the CC30 
cluster of strains is associated with its overall decreased virulence compared to its epidemic 
ancestor (Deleo et al, 2011). There are four different agr systems, and the presence of specific 
systems in MRSA has been correlated with differing sensitivities to vancomycin treatment, but 
whether this is a function of the specific agr system or a result of differing genetic backgrounds 
is yet to be determined (Seidl et al, 2011).
S. aureus possesses several other known TCSs, including the agr coordinating system 
saeRS, and the two agr antagonistic systems arlRS, and srrAB. saeRS upregulates a number of 
exoproteins including toxins and adhesive proteins through transcriptional interactions, and it is 
induced by the presence of RNAIII but inhibited by acidic pH, hypertonic NaCl concentrations, 
and certain antibiotics such as clindamycin, indicating that it functions as a downstream regulator
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heavily influenced by agr that may also add layers of regulation due to environmental factors 
(Mainiero et al, 2010; Novick and Jiang, 2003; Rogasch et al, 2006). arlRS activity results in the 
down-regulation of various exoproteins, counter to agr activity, and an arlRS mutant shows agr 
overexpression, indicating a mutually repressive role (Liang et al, 2005; Fournier et al, 2001; 
Fournier and Flooper, 2000). .wAB is inhibited by agr, and it responds to low oxygen stress to 
inhibit agr activation and decrease expression of virulence factors in order to lower metabolic 
burden and increase bacterial survival, representing a second mutually cross-inhibitory 
interaction with agr (Yarwood et al, 2000; Throup et al, 2001).
S. aureus produces a variety of transcription factors including the staphylococcal 
accessory regulation (Sar) family of DNA-binding proteins, of which SarA-plays a major role in 
regulation of virulence factors due to its interactions with the staphylococcal TCSs, where it 
often plays an inhibitory role through the binding of the regulatory element locus (Arvidson and 
Tegmark, 2001; Cheung and Zhang, 2002). SarA mutants produce heightened levels of 
exoenzymes and exotoxins, and decreased levels of adhesins.
Sar activity is heavily influenced by environmental signals due to its regulation by 
alternative sigma factors, of which oB is a major influence on the S. aureus virulon and SarA, 
which possesses a cB-dependent promoter. In response to environmental stresses, cB binds to 
promoter and transcriptional apparatus complexes and alter their stability, leading to 
upregulation of many adhesin genes and downregulation of exoproteins and toxins, a is 
necessary for transcription of genes involved in response to oxidative stress, including that of the 
carotenoid pigment for which S. aureus is named (Novick, 2006; Chan et al, 1998).
This brief snapshot of S. aureus global regulation shows a portion of the vast 
interconnected regulation network in which bacterial virulence factors are controlled by a
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combination of multiple levels of cross-inhibition and promotion.
1.13. Abscess model of A. aureus infection
The classical model of S. aureus infection is that of the suppurative abscess, the 
developmental phases of which mirror those the bacteria progress through in flask culture growth. 
The steps involved in the production cycle of the abscess model and related growth curve and 
major protein productions of S. aureus in an idealized flask culture are shown in Fig. 2.
In the initial colonization phase, the bacteria must localize and adhere to a site of 
colonization, which is often a wound site, where serum proteins like fibrin or thrombocytes are 
acting to form protective or sealing clots, and the previously described MSCRAMMs expressed 
on the surface of the bacteria recognize and bind these factors with high efficiency. This 
corresponds to the lag and early exponential phases of an in vitro bacterial culture, during which 
cell activities such as replication and synthesis of colonization factors are initiated. During this 
phase, any glucose available in the media will be fermented, resulting in a drop in the culture pH.
Once the adherent bacteria reach an optimal cell density, as sensed through the quorum 
sensing TCS module of the agr system, the activation of transcription of both the P2 and P3 
promoters of the agr locus results in a flurry of activity. Through the complex and condition- 
dependent interactions between the regulatory systems of S. aureus, expression of colonization 
factors is downregulated, and secretion of exoproteins, mainly virulence factors such as toxins 
and exoenzymes, is initiated. This corresponds to the post-exponential phase of an idealized flask 
culture, at which time glucose is depleted and acidity reaches its highest point, saeRS is in
Figure 2. Growth curve and abscess model of S. aureus.
The steps to the formation of a characteristic S. aureus abscess are shown, as well as prototypical 
gene products at different stages of the cycle and an idealized growth curve. A schematic 
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particular known to be sensitive to a moderate drop in pH, and its inhibition in acidic cultures is 
classically associated with a decline in exoprotein synthesis. Its sensitivity to environmental 
factors, which overrides the influence that RNAIII exerts, is thought to coordinate with the agr 
system and lend an additional level of regulation to the regulatory framework (Novick and Jiang, 
2003).
The accumulation of exoenzymes and toxins in the abscess model leads to recruitment of 
immune cells, mainly neutrophils, which then surround the bacterial growth to form a 
granuloma-like abscess. The neutrophils closest to the bacterial growth will engulf bacteria in an 
attempt to kill them prior to their own deaths, resulting in the formation of pus. The infection 
may then be resolved by immune system killing of the foreign cells, or thê  bacteria may utilize 
its secreted proteases and toxins to evade the immune cells, breaking free of the abscess in an 
invasive phase of infection and metastasizing to another area of colonization. This expression 
and secretion of exoproteins corresponds to stationary phase of a flask culture, during which the 
secreted factors play a role in acquisition of nutrients from less ideal sources such as larger 
proteins and lipids, which must be broken down, and require metabolic activity on the part of the 
bacteria, after which death occurs if no fresh nutrients are available. The glucose initially 
metabolized by the bacteria promotes a decreased pH due to the secretion of waste products such 
as acetic acid and lactic acid, depending on the aerobic condition of the culture, and the bacteria 
will reuptake these waste products to support a second round of growth, or for other purposes 
such as the acetylation of the bacterial peptidoglycan, increasing the pH of the culture both 
through the removal of the acids and through the secretion of amine wastes (Somerville et al, 
2003; Novick, 2006).
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1.14. Significance of staphylococcal biofilms and factors contributing to biofilm production
In addition to the classical abscess model, S. aureus also uses a biofilm mode of growth, 
the impact of which has more recently begun to be elucidated. A biofilm is a bacterial 
community, mono- or multi-species, that is characterized by increased resistance to antimicrobial, 
mechanical, or chemical stresses. Bacteria within the biofilm may have access to decreased 
levels of nutrients, slowing its growth and potentially generating highly resistant persister cells 
(Singh et al, 2009), while at the same time making the bacteria less sensitive to antimicrobials 
that target bacterial metabolic functions or division for their action. To help hold the community 
together and act as a physical barrier, the community secretes or builds a biofilm matrix 
consisting of variable components. These components consist of various proportions of 
polysaccharide (poly-A-acetyl glucosamine; PNAG), bacterial proteins heavily influenced by agr 
function and other regulatory networks (Vuong et al, 2000; Lauderdale et al, 2009), extracellular 
DNA (eDNA), and possibly some host factors. Surface proteins such as fibronectin-binding 
proteins and Protein A are described as important in attachment of bacterial biofilm to growth 
surfaces. Many S. aureus biofilms have been found to be susceptible to dispersal by proteases, 
indicating a major role of proteins in biofilm matrix formation, which could either be structural 
or a method of cross-linking and holding together structural eDNA (Boles and Horswill, 2011). 
Due to the reduced environmental stress on biofilm bacteria, S. aureus experience reduced 
selective pressure, leading to the generation of genetic variants that may show altered virulence 
(Yarwood et al, 2007), a phenotype also induced by detection of mechanical fluid sheer 
experienced often by the bacteria in a colonization phase (Castro et al, 2011).
S. aureus virulence may be attributable in part to its ability to form biofilms in infection 
settings, and S. aureus biofilms are important in the pathogenesis of infections of biological
implants, endocarditis, and osteomyelitis. The biofilm bacteria are highly resistant to antibiotic 
treatment and the shedding of bacteria into the bloodstream or other systems results in persistent, 
recurrent infection that can lead to sepsis, thrombosis, or other blockages. Previous work has 
established that in order to produce biofilms, S. aureus must encounter low pH conditions, which 
would then repress agr, sae, and sarA function and decrease the secretion of proteases and toxins 
(Vuong et al, 2000; Beenken et al, 2003). SspA has been implicated in the dispersal of biofilms 
in particular due to its homology with the Esp protease of S. epidermidis, which was found to be 
capable of dispersing S. aureus biofilms in co-culture (Iwase et al, 2010). This work will focus 
on the effect of deletion of the sspABC operon on the S. aureus biofilm growth phenotype.
The presence of eDNA in the biofilm matrix also indicates that bacterial autolysis is 
important for biofilm generation (Rice et al, 2007), and it has been found that this is an important 
early step in biofilm formation that allows proper maturation of the bacterial biofilm (Mann et al, 
2009). S. aureus autolysis is mediated by at least two autolytic enzymes, the well-characterized 
Atl and the more recently discovered Aaa (Heilmann et al, 2005). atl encodes two catalytically 
distinct peptidoglycan hydrolases, a A-acetylmuramoyl-L-alanine amidase (AM) and an endo-(3- 
¿V-acetylglucosaminidase (GL) in a large 120kD functional precursor that is processed into the 
smaller mature domains (Oshida et al, 1995). Peptidoglycan hydrolases are important for cell 
wall turnover, cell separation in division, and potentially play a role in antibiotic resistance 
(Sieradzki and Tomasz, 2006; Goessens et al, 1986). This work will concentrate on its role as a 
contributor to the biofilm growth phenotype and its potential altered function in the absence of 
exoproteases. SspA in particular is implicated, as its inactivation was found to cause pleiotropic 




Past and current research has led to a clearer understanding of the characteristics and 
mechanisms available to S. cmreus as a major human pathogen while leaving other questions 
unanswered. My hypothesis is that S. aureus encounters host and environmental stresses in 
colonization and invasion settings. In particular, decreased pH alters the expression patterns of 
the exoproteases of the sspABC operon, which modify the biofilm growth. Elimination of these 
proteases will therefore lead to alterations in the biofilm phenotype in terms of biofilm thickness 
and matrix cover.
Thus far, detection of protease mediated biofilm dispersal has been done through addition of 
exogenous proteases or indirectly through inactivation of broad-acting regulatory systems, so this 
work is the first to attempt to show a link between non-polar deletion of proteases encoded by S. 
aureus itself and its resultant biofilm growth phenotype.
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CHAPTER 2: MATERIALS AND METHODS
2.1. Growth of strains
Bacterial strains and colonies used in this study are listed in Table 1. S. aureus strains 
were maintained in Tryptic Soy Broth (TSB; BD Difco, Franklin Lakes, NJ) media at -80°C in 
20% glycerol (Biobasic, Markham, ON). S. aureus were streaked onto TSB or Brain Heart 
Infusion (BHI; BD Difco) plates containing 1.5% agar. Cultures were grown overnight in 5 mL 
of BHI or TSB in 14 mL culture tubes (VWR, Radnor, PA) at 37°C shaken at 280 rpm before 
subculturing into 25 mL of media in 125 mL flasks and shaken at 180 rpm for 6 or 18 hours for 
supernatant collection. Media was supplemented with antibiotic as necessary, using kanamycin 
(50 pg/mL), neomycin (50 pg/mL), erythromycin (10 pg/mL), tetracycline(2 pg/mL) and 
chloramphenicol (10 pg/mL).
For biofilm, zymograms, and assessment of the effect of pH and organic acids on 
protease production and activity, CA-MRSA-10 was grown in tryptic soy media made according 
to the recipe provided by Becton, Dickinson and Company (1.7% w/v Pancreatic digest of casein 
(BD, Franklin Lakes, NJ); 0.3% w/v Papaic digest of soybean (BD); 0.5% w/v Sodium chloride 
(EMD, Gibbstown, NJ); 0.25% w/v Dipotassium phosphate, (Sigma Aldrich, St. Louis, MO), 
and supplemented with 15 mM Glucose (EMD), 15 mM Acetic acid (EMD), or 15 mM Lactic 
acid (Sigma Aldrich) where indicated.
2.2. DNA gel electrophoresis
DNA was suspended in 6x DNA loading buffer diluted to 1x and separated on 0.8% 
agarose (Invitrogen) gels containing 0.05% ethidium bromide (EMD) and imaged using the 
GelDoc-It® Imaging System (UVP, Upland, CA).
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Table 1. Bacterial strains and recombinant plasmids used in this study
Strains or Plasmid Description Source
S. aureus:
RN4220 Restriction deficient lab strain Novick, 1991
RN6390 s/gB-deficient lab strain; identical to NCTC 
8325-4
Peng et al, 1988
SHI 000 rfoU-repaired mutant of RN6390; restored sigB 
function; produces robust biofilm
Horsburg et al, 
2002
RN6390 pMADwsspABC sspABC mutant of RN6390 This study
RN6390 pRN5528::sspABC Complemented sspABC mutant of RN6390 
using pRN5548a
Nickerson, 2009
Newman sarAw.km sarAw.km mutation in S. aureus Newman; 
produces elevated level of secreted proteases
Nickerson, 2009
Newman aurw.LacZ aurw.LacZ mutation transduced into S. aureus 
Newman, confers Erm resistance
Nickerson, 2009
Newman sspABCwtc sspABCwtc mutation of S. aureus Newman This study
Newman AaurSspABC Double protease deletion of S. aureus Newman This study
Newman AaurSspABCScpAB Triple protease mutant of S. aureus Newman This study
Newman AsarASspABC sspABCwtc mutation of S. aureus Newman 
sarAw.km
This study
USA300 sspABCwtc sspABCwtc mutation of S. aureus CA-MRSA 
USA300
This study
US A3 00 sspABCwtc 
pRN5548 wsspABC
Complemented sspABC mutant of USA300 
using pRN5548a
This study
US A3 00 sspABCwtc 
pRN5548a
Complementation vector negative control This study
S. aureus Isolates:
Newman Historical ST8 clinical isolate; ca 1952 Baba et al, 2008
USA300 ST8 community-acquired MRSA Li et al, 2009
Plasmids:
pRN5548a Promoterless derivative of S. aureus plasmid 
pRN5548, which contains the multiple cloning 
site of pUC18
Novick, 1991
pMAD Gram-positive allelic replacement vector Arnaud et al, 2004
pMAD AsspA BC: :tc pMAD carrying sspABCwtc deletion Passos,
unpublished data
pRN5548sspABC Recombinant pRN5548a carrying sspABC 
complementation operon
Nickerson, 2009
pDG1514 E. coli plasmid encoding TcR Guérout-Fleury et 
al, 1995
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2.3. Isolation of genomic DNA
S. aureus genomic DNA was isolated using Invitrogen Pure Link1'" Genomic miniprep kits 
following a slightly modified manufacturer’s protocol. Up to 2 x 109 cells were harvested via 
centrifugation prior to resuspension in 180 pL enzymatic lysis buffer, to which 15 pg/mL of 
lysostaphin (Sigma Aldrich) and 100 pg/mL of RNAse A were added. The mixture was 
incubated at 37°C for 30 to 60 minutes until turbidity was reduced, when 400 pg/mL of 
Proteinase K and 200 pL of Genomic Lysis/Binding buffer (Invitrogen, Burlington, ON) were 
added. The mixture was then incubated at 55°C for 30 minutes to complete lysis, which was 
followed by the addition of 200 pL of 100% ethanol. The lysate was passed through a 
PureLinktm Spin Column to bind through centrifugation, followed by washes with two supplied 
Wash Buffers before elution with the supplied Elution Buffer. The eluted product was tested for 
purity and DNA concentration using a Nanodrop ND-1000 spectrophotometer (Thermo Fisher, 
Wilmington, DE).
2.4. Isolation of plasmid DNA
Plasmid DNA was isolated using the Sigma Aldrich GenElute™ Miniprep Kit according 
to the manufacturer’s protocol, slightly modified for S. aureus. 1 mL or less, depending on 
cellular density, overnight culture was harvested via centrifugation (all centrifugation steps 
occurred at 12 000 g for the isolation of plasmid DNA) for 1 minute before resuspension in 200 
pL of provided Resuspension Solution, to which a provided RNAse A solution had been 
previously added. For isolation of S. aureus plasmids, 15 pg/mL of lysostaphin (Sigma Aldrich) 
was added. The mixture was incubated at 37°C for 30 minutes, after which 200 pL of Lysis 
Buffer was added and the mixture was inverted to mix briefly before the addition of 
Neutralization Buffer, both provided in the kit. Cellular debris and non-plasmid DNA was
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precipitated through centrifugation for 10 minutes, and the supernatant was transferred to a 
GenElute,M Miniprep Binding Column prepared with Column Prep Solution. The plasmid DNA 
was bound to the column membrane as the supernatant passed through the membrane during 
centrifugation for 1 minute, and the DNA was washed with provided Wash Buffer prior to 
elution with provided Elution Buffer. Eluent purity and concentration was determined using a 
Nanodrop ND-1000 spectrophotometer (Thermo Fisher).
2.5. Polymerase Chain Reaction, PCR purification, and recombinant techniques
Primers for PCR were designed and ordered from Sigma Aldrich, the full list of which is 
in Table 2, and genomic DNA was amplified in 50 pL volumes using 2 ng genomic DNA, 200 
pM deoxynucleotide triphosphates (Roche, Laval, QC), 0.3 pM each of forward and reverse 
primers, 1 x dilution of concentrated PCR reaction buffer containing 1.5 mM MgCb (Roche), and 
1.25 U of Taq polymerase (Roche). PCR products were purified using Bio Basic EZ-10 PCR 
Products Purification Kit according to the manufacturer’s protocol. The reaction mixture was 
mixed with 3 volumes of Binding Buffer 1 provided, and the mixture was transferred to an EZ­
IO Spin Column, where it incubated at room temperature for 2 minutes before centrifugation for 
2 minutes at 10 000 rpm to bind. The membrane was washed twice with provided Wash Buffer 
before elution, after which eluent purity and concentration was determined using a Nanodrop 
ND-1000 spectrophotometer (Thermo Fisher).
Enzymatic digests were performed with appropriate buffers diluted to 1 x concentrations 
and restriction enzymes diluted 1 in 20x (New England Biolabs, Pickering, ON) in volumes of 
20 pL. Substrate DNA amounts varied according to isolation eluent concentration. Ligations
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Table 2. Oligonucleotides used for PCR and plasmid modification
Primer Sequence Description
dSspABC-Fl CGCGATCCCGGTAAAGGATTTGTAAGGATT Amplifies 5’ flanking




dSspABC-F2 CCCGAATTCCAATTTCTCTACCAGCTCG Amplifies 3’ flanking 
region of j.s/?ABC
dSspABC-B2 GGAAGATCTGTAGGTGAAGACCAAATCCC operon
Flank_ABC-Fl TTACCGCTCAACCTGAAGG .V5/7ABC operon flanking 
detection primers
Flank_ABC-B2 CATTCTGTTCTGGTGGTGACC
Int_ABC-F2 C ATCCACAAC AAACGCAGTC sspABC operon internal 
detection primers
Int_ABC-B2 GCTCATAAACGATTGGTCGC — -
aurLacZ-F 1 GCTGTTTTTAAGATTTCAGGAGG aurwerm internal 
detection primers
lacZ-Rl TAACGCCAGGGTTTTCCC




GGTT ATCGTT AT ATT GCT GC AT C AG




were performed with T4 DNA ligase diluted 1 in 20x and T4 ligase buffer (New England 
Biolabs) diluted to 1 x concentration in a final volume of 20 pL. Ligation substrate amounts 
varied according to preparation concentration.
2.6. Bacterial transformation
10 pL volumes of plasmid preparations were electroporated into 80 pL of 
electrocompetent S. aureus cells, prepared by growing bacteria in 200 mL of culture to a final 
OD of 0.7 before triple-washing with ice cold 0.5M sucrose (EMD) and flash-freezing and 
maintenance at -80°C. The mixture was transferred into 2 mm electroporation cuvettes (VWR) 
after thawing on ice, and was pulsed under conditions of 100 Q resistance, 25 pF capacitance 
and a voltage of 2.5 kV using a Bio-Rad electroporator. 920 pL of TSB was added to the cuvette 
immediately after pulsing and inverted to mix, followed by incubation at 37°C before the 
mixture was plated on selective and/or differential TSB plates containing X-Gal and/or 
antibiotics as necessary and incubated overnight at 37°C or 30°C for amplification of 
temperature sensitive pMAD plasmid.
2.7. Construction of mutants
The sspABC operon deletion was generated using the pMAD plasmid vector, into the 
multiple cloning site (MCS) of which was inserted S', aureus strain Newman genomic DNA 
cloned from the upstream and downstream regions of the sspABC operon, flanking a tetracycline 
resistance cassette (TcR). The plasmid construct was first electroporated into strain RN4220, 
which will accept foreign DNA, and then moved to RN6390 through plasmid isolation and 
electroporation. The strains were maintained at 30°C to allow replication of pMAD from its 
temperature sensitive OriTS usable by S. aureus, and successful transformants were identified by
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their resistance to erythromycin (pMAD encoded), tetracycline (TcR encoded), and blue colour 
resulting from production of a beta-galactosidase that allowed the bacteria to metabolise X-Gal. 
The transformants were then grown at 42°C to eradicate the plasmid and allow the identification 
of a double recombination event that replaced the genomic sspABC operon of RN6390 with the 
plasmid TcR flanked by genomic flanking regions. The successful recombinants can be 
recognized by their white colour on X-Gal, lack of erythromycin resistance, and gain of 
tetracycline resistance. The recombinants’ sspABC deletion was then moved to strains Newman, 
Newman sarAwkm, Newman aurwLacZ, and USA300 using 085 initially before switching to 
®80a phage transduction. Donor strains were grown in TSB with 0.5 mM CaCf before mixture 
with the phage vector and plating onto TSB agar containing 2 mM CaCf. Transducing phages 
packaged lysed bacterial DNA fragments mistakenly from the donor strain RN6390 sspABCv.tc 
and injected the DNA into recipient strains, where a recombination event would replace the 
sspABC operon with the TcR at a low rate when the recipient was mixed with transducing lysate 
at a MOI of 0.1 or 1.0 before suspension in 1 mL of 0.02 mM sodium citrate. 200 pL of vector- 
recipient mixture was then added to 3 mL of phage top agar (0.265 g yeast extract, 0.265 g 
casamino acids, 0.578 g NaCl and 0.5 g agar in 100 mL ddLLO) and plated on TSB 
supplemented with 4 mM sodium citrate and antibiotic as necessary. Successful allelic 
replacement would result in colonies that were resistant to tetracycline, and these transductants 
were screened using both PCR and sequencing in and around the locus.
A triple mutant of strain Newman deficient in aur, sspABC, and scpAB encoded proteases 
was generated through phage transduction of the scpAB::km deletion into the aurSspABC double 
mutant, and the resultant mutant was therefore resistant to tetracycline, erythromycin, and 
kanamycin/erythromycin for selection.
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2.8. Complementation of sspABC mutants
Construction of the pRN5548sspA DC plasmid was completed as described for deletion of 
the sspABC operon, but using the high copy number pRN5548a plasmid that is maintained stably 
in S. aureus and confers plasmid encoded chloramphenicol resistance (Nickerson, 2009). The 
plasmid construct was isolated from RN6390 pRN5548s.spAi?C and electroporated into the 
sspABC mutant of USA300.
2.9. Protein profiles and Western blotting
Supernatant collected from 25 mL cultures was concentrated using 10% trichloroacetic 
acid (TCA; 20% stock) (Alfa Aesar, Ward Hill, MA) precipitation and separated using standard 
8% bis-acrylamide gels run at 100 volts for approximately 100 minutes. Protein bands were 
visualized with Coomassie stain. Gels for immunoblotting were transferred to FluoroTrans 
PVDF membranes (Pall, Port Washington, NY) and incubated with rabbit serum antibody for 
SspA for two hours before washing and incubation with IRDye800 linked donkey anti-rabbit IgG 
(Rockland Immunochemicals, Gilbertsville, PA). IRDye signal was visualized using the Odyssey 
fluorescence scanning system (Li-Cor, Lincoln, Neb.).
2.10. Murine infection model
The murine infection model was performed based on the UWO Animal Care and 
Vetinary Services (ACVS) protocol number 2010-211.7 week old female albino Balb/c mice 
(Charles River, Wilmington, MA) were housed in UWO ACVS facilities in positive and negative 
containment quarters in micro-isolator shoebox colonies. They were challenged with 100 pL of 
various strains of S. aureus normalized to 5 x 106 to 1><107 cfu/inoculum, through tail vein 
intravenous (IV) injection, and monitored for 96 hours. Early sacrifice occurred under conditions
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of unacceptable distress such as lack of mobility or loss of 25% of initial body mass. After 96 
hours, mice were sacrificed through 200 pL 1:1 Euthanyl: H2O (ACVS; controlled drug license 
available) intraperitoneal (IP) injection, and their kidneys, liver, spleen, and heart were harvested 
for cfu enumeration post homogenization, or for histopathology processing using a Leica 
ASP300 fully enclosed paraffin wax tissue processor (Leica, Concord, ON) followed by Microm 
HM335E Microtome sectioning (Leica) and Gram or Hematoxylin and Eosin staining with a 
Leica Autostainer XL (Leica). Histopathology processing was performed by UWO Molecular 
Pathology core services.
2.11. Biofilm assay
Biofilm assays were preformed in culture treated 96 or 6-well Nunclon Surface plates 
(Nunc, Rochester, NY). Biofilm was grown in previously described supplemented Tryptic Soy 
media buffered with 0.1M MES buffer (Sigma Aldrich) or 0.1M Bis-Tris buffer (Sigma Aldrich) 
to pH 5.5, 6.0. 7.0, or unbuffered. Culture treated Thermanox plastic coverslips (Nunc) were 
leaned against the sides of the 6-well plates to provide a surface for biofilm attachment. ~ 5 X 
107 bacteria were inoculated into each well of 6 well plates containing 5 mL media and grown 
statically at 37°C for 48 hours. The coverslips were then processed for electron microscopy as 
previously described (Williams and Bloebaum, 2010). Briefly, coverslips were submersed in 
fixative solution containing 2.5% glutaraldehyde (Sigma Aldrich), 0.75% Ruthenium Red 
(Sigma Aldrich) in 0.2M cacodylate buffer pH 7.4 (Sigma Aldrich) for 24 hours after an initial 
20 min treatment in preincubation buffer of the same formula with 50 mM L-lysine added. The 
coverslips were then washed in cacodylate buffer 3X for 10 min, submersed in a 2% solution of 
osmium tetroxide (OsCL; Sigma Aldrich) in cacodylate buffer for 2 hours. Coverslips were 
washed 3X for 10 min in cacodylate buffer a second time, and finally dehydrated in increasing
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concentrations of ethanol (70%, 95%, 100%) 3x for 20 rain each and desiccated. Biofilm on the 
coverslips were coated with gold for imaging at Surface Science Western.
Approximately 2 x 106 bacteria were inoculated into each well of 96 well plates 
containing 200 pL media and grown statically at 37°C for 48 hours. 96 well plates were then 
washed once with PBS, and biofilm was dried onto the surfaces of the wells. Wells were 
incubated at room temperature with 1% crystal violet (Sigma Aldrich) dye for 30 min, washed 
with distilled water until wash water ran clear, and remaining crystal violet was extracted with 
100% methanol (BD). Extracted dye was diluted as necessary and read at 595mn using a 
microplate spectrometer (Bio-Rad, Hercules, Calif.).
2.12. Proteolytic assay
Proteolytic activity assays were performed with supernatant collected from 25 inL 
cultures or from biofilm assay plates. Supernatants were normalized to maximum optical density 
in 490 uL, completing with sterile Milli-Q H2O (filtered with Milli-Q system; Millipore, 
Billerica, MA), dependent on initial optical density of growth cultures. Mixtures were buffered 
using 460 uL proteolytic incubation buffer, which was designed to permit activity of all three 
major classes of proteases produced by S. aureus through the supply of necessary co-factors. 
Incubation buffer contains 0.02M sodium phosphate (HNa2PC>4 titrated with H^NaPC^ to pH 7.4; 
EMD), 0.15 M sodium chloride (NaCl; EMD), and ImM L-cysteine (Alfa Aesar). 50 uL of 0.2% 
w/v FITC-labelled casein (Sigma Aldrich) were added, and the mixture incubated at 37°C in the 
dark for 2.5 hours. 200 uL of TCA were used to precipitate remaining undigested casein, and 
solubilised FITC was quantified using the Cary Eclipse fluorometer (Varian/Agilent, Palo Alto, 
Calif.) at excitation 485nm, emission 535nm.
42
2.13. Statistics
Statistical analyses were performed with Graphpad Prism version 5.0c for Mac, 
GraphPad Software, San Diego California USA, www.graphpad.com.
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CHAPTER 3: RESULTS
3.1. Deletion of sspABC operon in S. aureus and generation of double and triple protease 
mutants
The purpose of this study was to determine the effect that proteases of the sspABC operon 
and other major proteases produced by S. aureus exert on its biofilm growth phenotype and 
elucidate overall links to virulence. To that end, the sspABC operon of S. aureus RN6390 was 
deleted (Fig. 3), and the mutation was then transferred to strains Newman, Newman sarA::km, 
Newman aurr.lacZ, and USA300 through phage transduction.
A scpABwkm mutation was transduced into the isogenic mutant of strain Newman lacking 
all proteases of the SPC in order to generate a triple protease mutant that lacks all major secreted 
proteases with characterized implications in virulence. The Staphopain A knockout was 
generated through the same method as the sspABC deletion (Ngai, 2011). The deletion was 
verified through PCR using flanking and internal primers NMN-ScpA-Flank-Fl, NMN-ScpB- 
Flank-Bl, and NMN-ScpA-Int-Fl, NMN-ScpB-Int-Bl respectively, and sequencing. Sequences 
of primers indicated in this section are shown in Table 2.
3.2. Phenotypic characterization of A sspABC
Secreted proteins of the sspABCv.tc mutant were collected and concentrated through TCA 
precipitation for comparison against the protein profile of wild type USA300. Western blot 
analysis was also used to phenotypically verify deletion of the sspABC operon through immuno­
detection of SspA. Figure 4 shows that no SspA is detectable in the supernatant of USA300 
sspABCv.tc when compared to WT USA300. The protein profile shows that other than bands 
corresponding to the proteases of the sspABC operon, few other differences in secreted protein
A) The sspABC operon in wild type Newman and the binding locations of primers 
dSspABC_Fl, dSspABC_Bl, dSspABC_F2, and dSspABC_B2, which were used to 
clone the 5' and 3' flanking regions of the sspABC operon. Primers and sequences are 
listed in Table 2.
B) DNA electrophoresis gel of PCR products using flanking and internal detection 
primers Flank_ABC_Fl, F l a nk AB CB l ,  and Int_ABC_F2, Int_ABC_B2 respectively. 
Lane 1 shows USA300 wild type genomic DNA amplified with internal detection primers 
annealing within the sspABC operon. Lane 2 shows no product using the same primers in 
the USA300 sspABC. :tc mutant. Lanes 3 and 4 show wild type and mutant genomic DNA 
amplified using external primers, generating products that differ in size by 0.5 Kb, 
corresponding to the difference in size between the sspABC operon and the smaller TcR
Figure 3. Steps in generating and confirming a deletion of the sspABC  operon.
cassette.
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A Newman SspABC operon and flanking regions
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Supernatants of USA300, USA300 sspABCv.tc, USA300 sspABCv.tc pR N 5548::s^5C , and 
USA300 sspABCv.tc pRN5548a were collected and analyzed for protein expression through 
coomassie staining and immunoblotting. Arrows point to the locations of mature SspA and SspB 
in USA300. The SspA immunoblot shows SspA secretion in USA300 wild type and the 
complemented mutant USA300 sspABCv.tc pRN5548::.«^5C, but not in the sspABC mutant or 
mutant with pRN5548a plasmid alone.








expression exist, indicating that deletion of the operon has not caused any adventitious 
pleiotropic effects. The expression profile shows the absence of the various protease activation 
intermediates as well as a few secreted proteins processed by proteases of the sspABC operon in 
the deletion mutant. The sspABC deletion was complemented in trans through expression of the 
operon on high copy number plasmid pRN5548a, and as seen in the protein profile and Western 
blot, overexpression of proteases occurred, whereas complementing with pRN5548a alone did 
not restore SspA production when moved into the mutant as a control.
Mass spectrometry, to assess and identify differences in secreted protein profile, was also 
performed on 6 and 18 hour supernatants of USA300 WT and AsspABC mutant, as well lab 
strain SHI000, which is a derivative of NTC 8325-4 that has been repairedior a  function and 
produces low secreted protease levels and robust biofilm growth. SHI000 is included in this and 
following results as a control for low protease production and high biofilm growth, both areas in 
which it behaves significantly different compared to USA300. Other than differences in protease 
expression, USA300 sspABCv.tc showed higher levels of autolysin precursor in 6 h supernatant 
compared to wild type. Another band of approximately 30 kD was upregulated in the protease 
mutant of USA300 but could not be identified via mass spectrometiy. Figure 5 shows protein 
bands of interest and their identities, while the corresponding accession numbers and percent 
confidence values are displayed in Table 3.
3.3. USA300 produces elevated levels of exoprotease but not exotoxin in media buffered to 
pH 5.5 and 6.0 in the presence of glucose
Glucose is the primary and preferred carbon source used by S. aureus, and it has been 
found to be necessary for biofilm formation. The classical model states that as glucose is
Protein profile of culture supernatants of USA300, USA300 sspABCv.tc, and SH1000 grown in 
unbuffered TSBG for 6 or 18 hours. Bands identified by mass spectrometry: 1) lipase, 2) SspA, 3) 
LukF, 4) Autolysin precursor, 5) Hla, autolysin (glucosaminidase domain), 6) LukS, 7) autolysin 
(amidase domain), SspB, 8) unidentifiable.




2 0 0  --------
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Table 3. Name, confidence score, and accession number(s) of secreted proteins identified by 
mass spectrometry.




l Lipase 100 57651062
2 SspA 100 15924038
3 LukF 100 9635192
4 Autolysin precursor 100 49483217,21282665
5 Hla 100 15924153
Autolysin (GL) 100 32968086, 2506027
6 LukS 100 21283108





fermented, the decrease in pH caused by accumulation of fermentation products inhibits agr 
activity, resulting in decreased levels of ogr-regulated toxins and enzymes, including proteases 
that would otherwise disperse the biofilm growth. According to this model, growth of S. aureus 
in glucose or in decreased pH conditions would therefore result in lowered production of 
proteases. pH is most commonly adjusted to 5.5 in the literature to represent acidity conditions 
encountered by colonizing bacteria on human skin. In contrast, as seen in Figure 6 , SspA 
protease production was dependent on the presence of glucose. More protease is detectable at 6  h 
growth in the various media than at 18 h growth, and the most SspA is detectable in media 
buffered to pH 5.5. The intensity of the SspA bands decrease as the pH of the media increases. 
There is also a reduction in the amount of SspA protein at 18 h, likely due to instability of the 
SspA protease. Table 4 lists the pHs measured before, during, and after growth of USA300 in 
buffered and unbuffered TSB.
Alpha toxin (Hla) production was also assayed under these pH conditions. Although Hla 
is under the control of the agr locus similarly to SspA, it is translationally de-repressed by 
RNAIII in a more direct mechanism of regulation, and the condition in which the most SspA was 
produced (pH 5.5) corresponded with the condition in which Hla production was dramatically 
decreased. This suggests additional sources of regulation that layer upon ngv-based 
transcriptional regulation of SspA. The proteases may also play a role in the degradation of Hla
in culture supernatant.
Figure 6. Immunoblots for detection of SspA or Hla toxin in culture supernatant of 
USA300.
Cultures were grown for either 6  h or 18 h in TSB or TSB containing 15 mM glucose. The TSBg 




Table 4. pH and growth data of USA300 in chemically-defined media containing glucose, 
acetic acid or lactic acid in buffered and unbuffered media.
pHi pHm pH, OD600i OD600,
TSBg 7.05 6 . 0 2 7.85 0 .1 9.02
TSBg 0.1 M MES pH 5.5 5.48 5.45 5.92 0 . 1 5.72
TSB 15 mM acetic acid 6 . 6 8 5.44 7.96 0 . 1 4.56
TSB 15 mM acetic acid 
0.1 M MES pH 5.5
5.45 5.38 5.87 0 . 1 2 . 6 6
TSB 15 mM lactic acid 6.81 5.96 8.32 0 . 1 6.04
TSB 15 mM lactic acid 0.1 
M MES pH 5.5
5.52 5.43 5.75 0 . 1 4.15
* pH was measured initially and at 6  (mid), and 18 (final) hours, while OD600 was measured 
initially and 18 hours.
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3.4. Increase in SspA levels of USA300 corresponds to increased overall proteolytic activity
As shown in Figure 6 , optimal SspA production occurred at acidic pH, and was also 
dependent on glucose as a substrate. To determine how protease activity was influenced by this 
variation in SspA production, the same culture supernatants were assayed for total protease 
activity using FITC casein as a substrate (Fig. 7). At 18h of growth, protease activity of USA300 
grown in unbuffered TSBg was significantly greater compared to culture grown in TSB alone, 
confirming that glucose is needed for optimal protease production. Moreover, the protease 
activity of US A3 00 grown in TSBg pH 5.5 was significantly greater than culture grown in TSBg 
pH 7.0. In addition, when grown in TSBg pH 5.5, the protease activity of USA300 sspABCv.tc 
was nearly 3-fold less than wild type USA300, confirming a major contribution of SspA and 
SspB. Protease activity was also compared to S. aureus strain SHI 000, which produces robust 
biofilm, and in previous work was used to assess the influence of secreted proteases on biofilm 
production. The data reveal that SHI000 had negligible protease activity, being far less than that 
of protease deficient mutant USA300 sspABCv.tc.
In contrast to the 18h cultures, protease activity at 6 h was much lower despite maximal 
SspA immunoblot detection occurring at the earlier time point, indicating that SspA was likely 
detected in an inactive form. The proteolytic activity that does occur shows a trend of increasing 
as the pH of the culture medium was increased from 5.5 to 7.0. This may reflect the activity of 
the metalloprotease Aureolysin, which is produced in mature form prior to the appearance of the 
SspA and SspB precursors, and is susceptible to rapid autocatalytic degradation beyond 6 h of 
growth (Nickerson et al, 2008).
Figure 7. Proteolytic activity of USA300 and USA300 sspABCr.tc grown under various pH 
conditions.
18h cultures of USA300 and its sspABCv.tc mutant were grown in TSB with or without glucose 
supplementation and buffered to different pHs. SHI000 is included as a control showing low 
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3.5. Effect of other carbon sources on SspA production
Although our data reveal that glucose promotes optimal production of secreted protease, 
another tenet of the biofilm model is that acidic end products of glucose fermentation, acetic and 
lactic acid, are metabolized on depletion of glucose to promote additional growth. Acetic acid 
also has an important role in biofilm development by promoting expression of autolytic activity, 
which is required for release of eDNA, a structural component of biofilm matrix (Rice et al, 
2007). It is therefore of interest to evaluate the influence of acetic acid and lactic acid production 
of SspA.
As seen in Figure 8 , compared to TSB alone, medium supplemented with 5 mM acetic 
acid promoted a slight stimulation in production of SspA, an effect that appeared to diminish at 
10 mM acetic acid. In a separate experiment when TSBg buffered to pH 5.5 was supplemented 
with acetic acid, SspA production decreased in a dose-dependent manner and was abrogated at 
20 mM acetic acid. Supplementation of glucose-free media with acetic acid resulted in a 
dramatic decrease in final cell density (less than half of final OD of S. aureus grown in TSBg, 
Table 4) at 18h, while this was not observed with lactic acid.
Conversely, Figure 9 shows that addition of lactic acid to TSB results in increased 
production of SspA. These data suggest that while lactic acid is imported and utilized as a carbon 
source, acetic acid inhibits growth, and results in lower SspA production, possibly as a result of 
the growth inhibition. It is therefore likely that acetic acid is not used as a carbon source. 
Supplementation with neither organic acid resulted in similarly high levels of SspA production 
compared to those facilitated by glucose supplementation, so acetic acid and lactic acid were not 
used in further experiments designed to elucidate the effect of proteases on various growth 
phenotypes.
A) Unbuffered TSB made without glucose was supplemented with increasing 
concentrations of acetic acid.
B) Increasing concentrations of acetic acid in buffered tryptic soy media made with 
glucose show a dose-dependent decrease in protease production.
Figure 8. The effect of acetic acid supplementation on protease production levels.
61
T S B
A c e ta te  (m M )  




A c e ta te  (m M ) o 5
S sp A
pH  5 .5
10 20 3 0
G lu co se  +
U S A 3 0 0
Unbuffered TSB made without glucose was supplemented with increasing concentrations of 
lactic acid. Arrows point to the likely ran distance of SspA.
Figure 9. The effect of lactic acid supplementation on protease production levels.
TSB
L a c ta te  (m M )  0
W T  +
10 15
+ -  +
A sspABC 
k D a
+ -  + + -  +
64
3.6. The sspABCr.tc mutant of USA300 produces significantly more biofilm than wild type 
USA300
The classical model of S. aureus biofilm growth states that glucose supplementation of 
growth media is necessary for biofilm growth and maturation, as metabolism of glucose results 
in the decrease in pH that inhibits agr-regulated exoproteases, including SspA (Boles and 
Horswill, 2008; Somerville et al, 2003). However, having ascertained that media buffered to an 
acidic pH corresponds to increased protease production and activity, the effect of glucose 
supplementation and buffering of media to various pHs on the biofilm growth phenotype was 
then examined. In a microtitre plate biofilm assay (Fig. 10), USA300 and USA300 sspABCv.tc 
were grown in TSBg and buffered to different pHs. In all pHs, the sspA BC:'Jc mutant produced 
significantly more biofilm than the wild type (** = p<0.001). Unbuffered TSBg supported less 
biofilm growth than unbuffered TSB that lacked glucose, which supports the claim that proteases 
are responsible for the dispersal of biofilm, since supplementation with glucose promotes 
increased protease expression and activity. The highest levels of biofilm growth occurred in 
TSBg and buffered at a pH of 5.5 or 6.0, conditions which, counter-intuitively, also resulted in 
the highest proteolytic activity.
3.7. High biofilm production is correlated with low proteolytic activity
Though low pH is correlated with high protease production and proteolytic activity in 
flask cultures, this is not necessarily representative of proteolytic activity in the biofilm growth 
mode. S. aureus is known to differentially express many different gene products in its biofilm 
phenotype compared to planktonic growth. In order to determine the amount of proteolytic 
activity displayed by S. aureus during biofilm growth, USA300 and USA300 sspABCv.tc were
Strains were grown in buffered or unbuffered TSB or TSBg as indicated. After 48h growth, 
biofilm was quantified by staining with crystal violet (A595). Strain SHI000 is included in 
unbuffered TSBg and TSBg buffered to pH5.5 as a positive control known to produce robust 
biofilm. ** p<0 .0 0 1 .
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grown in a microtitre plate biofilm assay in TSBg and buffered to different pHs. Supernatant was 
collected from each of the microplate wells, pooled, and assayed for proteolytic activity. As seen 
in the representative trial presented in Figure 11, the amount of proteolytic activity is negatively 
correlated with robustness of biofilm growth. In this trial, when biofdms were grown in TSBg 
buffered to pH 6.0, USA300 showed anomalously low proteolytic activity, but the data is 
included to emphasize that when there was no difference in proteolytic activity, there was also no 
significant difference between biofilm growth of the wild type compared to the mutant.
Compared to the amount of proteolytic activity exhibited by supernatant collected from flask 
cultures (Fig. 7), the supernatant collected from biofilm growth showed lower overall proteolytic 
activity despite the increased amount of time in which the biofilm was allowed to develop. The 
proteases produced by the biofilm bacteria may have degraded before the proteolytic assay was 
performed due to the long length of time, or the biofilm communities may be producing lower 
levels of proteases altogether. Due to the static nature of the biofilm, any secreted products may 
be captured within the matrix of the biofilm and thereby concentrated, allowing even a small 
amount of secreted proteins to cause a significant effect. All differences are significant to a p- 
value of less than 0 .0 0 1 . (** = p<0 .0 0 1 )
3.8. USA300 sspABCr.tc shows a different qualitative biofilm growth phenotype
In addition to producing more quantifiable biofilm adherent to the bottom and walls of 
serum-coated wells in microtitre plate assays, the sspABCwtc mutant of USA300 produces 
clumps of bacteria visible to the naked eye. As seen in Figure 12, SH1000, a known robust 
biofilm maker, tends to produce a uniform biofilm in a thick mat without any visible adherent 
clumps. USA300 produces very little visible biofilm, as does USA300 sspABCwtc complemented
Biofilm assay supernatant was collected and pooled from a microtitre plate biofilm assay in 
which USA300 and USA300 sspABCv.tc were grown in TSBg buffered or unbuffered to various 
pHs. The top panel shows biofilm production in the various growth conditions, and the bottom 
panel shows the proteolytic activity of the supernatant collected from the microtitre plate wells in 
which the biofilms grew for 48 h. Soluble FITC was included in 0.1 and 0.25 pg amounts as 
standards. ** = p<0 .0 0 1 :
Figure 11. Correlation between biofilm growth and proteolytic activity.
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Biofilm of each strain were generated in rows of 12 duplicate microtitre plate wells coated with 1% 
human serum in PBS and grown in TSBG buffered to pH 5.5 with 0.1M MES. An uninoculated 
blank row of wells is shown below biofilm rows.
Figure 12. Physical characteristics of biofilm grown in microtitre plate wells.
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in trans with pRN5548::sspABC, whereas USA300 sspABCv.tc and USA300 sspABCv.tc 
containing only pRN5548 both produce comparable biofilm density and clumping.
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3.9. Scanning electron microscopy of biofilm growth phenotype
Further detail on the phenotypic differences between the biofilm growth modes of 
USA300 wild type and protease-null mutants was elucidated through preparation of biofilm on 
serum coated plastic coverslips half-submerged in TSBg pH 5.5. Biofilm was found to grow in 
distinct zones of thickness, so the cover slips were trimmed after growth to isolate areas of true 
biofilm growth located between the tide line, which represents the liquid/air interface at which 
point debris and bacteria will adhere to the cover slip due to evaporation of media, and the thick 
growth at the bottom of the cover slip, which represents bacteria that had settled through 
sedimentation. Scanning electron micrographs of US A3 00 biofilm display adherence and growth 
that most typically appeared as a thin monolayer covered with biofilm matrix, though there were 
also areas in which the bacteria formed thicker, clumped growth that was not covered with 
matrix, suggesting that the bacteria had burst free of the matrix cover and grown upwards when 
uncovered (Fig. 13-A). In other areas of biofilm growth, a thicker, uniform mat of bio film had 
developed that was covered with a layer of matrix material, as shown in the cross-sectional 
image in Figure 13-B. The cross-section of this mat was measured to be approximately 5.5 pm 
thick.
As seen in Figure 14, USA300 sspABCv.tc grows thicker biofilm in which growth is 
consistently covered with at least some biofilm matrix. The matrix appears to coat the top surface 
of the biofilm but does not appear throughout the bacterial cells packed into the biofilm mat, 
which reaches 17.5 pm in thickness (Fig. 14-B). The micrographs show flat regions of biofilm
Top view (A) and cross section (B) images were taken of USA300 biofilm grown on a plastic 
cover slip coated with human serum and grown in TSBG buffered to pH 5.5. Biofilm mat was 
measured to be 5.5 pm in height.
Figure 13. Scanning electron micrographs of USA300 biofilm.
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Top (A, C) and cross section (B, D) views were taken of USA300 AsspABC biofilm grown on a 
plastic cover slip coated with human serum and grown in TSBG buffered to pH 5.5. The upper 
panels show representative thick biofilm growth with areas of mat reaching 17.5 pm in height. 
The lower panels show one of the adherent clumps noticeable in microtitre plate biofilm as a 
towering biofilm community filled with bacteria and measuring 50 pm in height.
Figure 14. Scanning electron micrographs of USA300 sspABC::tc biofilm.
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growth separated by zones containing only sparsely distributed single cells scattered on the 
growth surface, but the shapes of the flat regions suggest that they were initially components of a 
single thick, uniform mat that had cracked and split into the pieces visible in microscopy due to 
the desiccation process during preparation of the biofilm for microscopy (Fig. 14-A). The 
biofilm formed by the protease mutant was most likely continuous, thick mat, unlike that of 
USA300 wild type, which had zones of mat interspersed with zones of near monolayer growth 
(Fig. 13-A). The large clumps of bacteria that had been visible to the naked eye in the microtitre 
plate biofilm assays are massive communities of bacteria that tower to heights of 50 or more pm 
(Fig. 14-C and D). There seems to be a link between loss of proteolytic activity and thickness of 
biofilm growth, and the massive bacterial communities seen in the protease-null mutant are 
likely the result of decreased rate of biofilm dispersal or degradation of structural materials.
3.10. Deletion of the sspABC  operon in USA300 produces no overall change in virulence in 
a mouse infection model
The differences established between wild type and protease-deficient mutant in the 
biofilm model of growth may reflect changes in the other major mode of colonization and 
infection S. aureus utilizes: the abscess model. S. aureus is heavily associated with various 
abscess-based infections, and US A3 00 is most often found in the community in the form of 
suppurative abscesses and other soft-tissue infections. Its more serious forms of infection are 
often the result of abscess formation within internal organs, including acute pyelonephritis, an 
inflammation of the kidney. For these forms of infections, a mouse bacteraemia model was used, 
in which the mice were challenged with wild type and protease-null mutants in order to 
determine the effect of protease mutations on the organ abscess mode of infection following
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challenge via bacteraemia. S. aureus was normalized to a challenge inoculum of approximately 5 
x 106 CFU/dose and introduced to Balb/c albino mice through tail vein injection. S. aureus will 
then pass through and colonize the kidney first, be carried by the bloodstream to the heart, from 
where it will spread to various other organs. This model generates an acute systemic infection in 
which the mice are sacrificed after a 96 hour incubation period or when the mice are deemed too 
sick before the incubation period has elapsed, and its kidneys, liver, spleen, and heart are 
harvested and the bacterial load in each organ is enumerated in terms of CFU/organ. Figures 15 
to 17 show the pooled results of several mouse bacteraemia challenges using strains Newman, 
USA300, USA300 sspABCwtc, and USA300 sspABCwtc pRN5548.s-.s-p.4i5C. Figure 15 shows 
bacterial load in kidneys and spleen, in which there was no significant difference between 
US A3 00 and its isogenic variants, although there was a slight, nonsignificant trend toward 
increased bacterial load in the kidney in mice challenged with USA300 sspABCwtc as compared 
to USA300 wild type. Figure 16 shows bacterial load in the liver and heart, where there is a 
small but significant difference in liver bacterial load between USA300 sspABCwtc and USA300 
sspABC::tc pRN5548::sspA BC. In general, strain Newman was recovered from mouse organs in 
greater number, with significant differences in the liver, spleen, and heart. Strain Newman 
exhibits very low proteolytic activity due to an SNP in its saeRS locus that results in increased 
production of colonization factors and decreased production of exoenzymes and exotoxins. This 
may result in better adherence and evasion of the immune system because of the decreased 
amount of inflammatory virulence factors. Newman is noted to produce large abscesses in mouse 
kidneys. There were no overall significant differences in virulence measured through weight loss 
of the challenged mice, as seen in Figure 17.
Organ CFU counts comparing strains Newman, USA300, USA300 sspABCwtc, and USA300 
sspABCv.tc pRN5548::sspABC. These are pooled results from several trials, so N varies from 
strain to strain and are as follows: Newman 30, USA300 18, USA300 sspABCwtc 20, USA300 
sspABCwtc pRN5548::55/7^45C 3. ** p<0.001
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Figure 16. Infection of liver and heart by S. aureus USA300 and variants.
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Organ CFU counts comparing strains Newman, USA300, USA300 sspABCv.tc, and USA300 
sspABCv.tc pRN5548: .sspABC. These are pooled results from several trials, so N varies from 
strain to strain and are as follows: Newman 30, USA300 18, USA300 sspABCv.tc 20, USA300 
sspABCv.tc PRN5548::ss/?vi5C 3.
Figure 17. Weight loss in mice challenged with S. aureus.
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3.11. Deletion of subsequent exoproteases in strain Newman produced no overall change in 
virulence in a mouse infection model
As USA300 presents difficulties in the construction of multiple deletions due to its innate 
resistance to many of the common antibiotic selection markers, double and triple protease 
mutants were constructed in strain Newman, which is also a member of ST-8, and so is 
genetically similar to USA300. As shown in Figures 18 and 19, no overall difference in virulence 
as seen in the weight loss of the challenged mice was detected, and as described in the previous 
section, Newman and all its derivatives produce higher CFU per organ rates than USA300, likely 
due to its production of excess colonization factors and decreased toxin and protease output. A 
mutant of Newman deficient in action of the sarA transcriptional regulator was included as a 
control showing the effect of challenging mice with a variant known to display elevated protease 
and toxin production. The sarA mutant had significantly lower CFU per organ counts than other 
variants of Newman, indicating that this experimental protocol is sufficient for detection of 
phenotypic differences resulting from pleiotropic alterations to secreted protein levels. Figure 18 
shows the double protease deletion of Newman generated a higher CFU/organ count in the 
spleen, but this difference was very slight and on the cusp of significance. The triple protease 
mutant produced lower CFU/organ counts in the spleen than the double mutant despite 
possessing the same deletion of all proteases of the SPC, suggesting that although a mutant 
deficient in SPC proteases was able to better colonize mouse kidneys, the lack of all major 
secreted proteases was perhaps detrimental to the ability of the bacteria to colonize. The increase 
in CFU/organ count was also present in the heart, as seen in Figure 19. The presence of two 
organs in which there was a significant increase in CFU load in mice infected with a mutant 
deficient in all proteases of the SPC suggests that the proteases may have an effect on
Organ CFU counts comparing strain Newman with its single, double, and triple mutants. These 
are pooled results from several trials, so N varies from strain to strain and are as follows: 
Newman 30, Newman sspABCwtc 20, Newman aur::LacZ 20, Newman ÀaurSspABC 17, 
Newman àaurSspABCScpAB 10, Newman sarAv.km 10, Newman AsarAsspABC 10.
* p<0.05 ** p<0.001













Organ CFU counts comparing strain Newman with its single, double, and triple mutants. These 
are pooled results from several trials, so N varies from strain to strain and are as follows: 
Newman 30, Newman sspABCr.tc 20, Newman aurr.LacZ 20, Newman AaurSspABC 17, 
Newman AaurSspABCScpAB 10, Newman sarAr.km 10, Newman AsarAsspABC 10.
Figure 19. Infection of liver and heart by S. aureus Newman and variants.
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distribution of S. aureus within the organs by allowing the bacteria to spread invasively, though 
this would need to be confirmed for consistency and qualitatively through histopathology. There 
was no difference in overall virulence between Newman and any of its protease-deficient 
variants in terms of weight loss.
3.12. USA300 and its sspABCr.tc mutant show differences in their distribution pattern in 
mouse kidneys
In order to further elucidate any effect deletion of the proteases of the sspABC operon may have 
on the colonization patterns or distribution of USA300 despite lack of difference in overall 
virulence, kidneys of mice infected by USA300 or USA300 sspABCr.tc were fixed in formalin 
and sectioned prior to Gram and H&E staining for bacterial and eukaryotic cells respectively. As 
seen in Figure 20, histopathology samples comparing mouse kidney infected with USA300 and 
USA300 sspABCr.tc show some differences in their distribution of bacteria. While USA300 wild 
type forms abscesses within the kidney, it can also spread in a diffuse pattern that is not seen in 
the sspABCr.tc mutant. A second difference is the observation that wild type USA300 will 
infiltrate glomeruli while USA300 sspABCr.tc mainly occupies kidney tubules, suggesting that 
the proteases of the sspABC operon may enable S. aureus to spread and invade host tissues more 
effectively.
Gram and H&E stains were applied to kidney cross sections of mice challenged with US A300 (A) 
and USA300 sspABCwtc (B). Top two segments of each panel show Gram stain, and bottom two 
segments of each panel show H&E staining. Right segments of each panel show a 200 x 
magnification of boxed areas in the corresponding left segment.




As the role of staphylococcal biofilms in infectious disease is further elucidated, current 
research has begun to focus on the polysaccharide independent method of biofilm formation 
utilized by clinically relevant clones of methicillin-resistant S. aureus (O’Neill et al, 2007; 
Lauderdale et al, 2009; Boles et al, 2010). Due to an up to six-fold increase in antibiotic 
resistance of biofilm associated S. aureus (Boles and Horswill, 2008), staphylococcal biofilms 
are notoriously difficult to eradicate, and the biofilm growth phenotype is heavily associated with 
the persistence and chronic nature of biofilm-associated infections. Although initial work on 
biofilm, especially in S. epidermidis, suggested that the biofilm mode of growth is heavily 
dependent on its extracellular polysaccharide matrix (Kaplan et al, 2004), itJbecame evident that 
the majority of S. aureus clinical isolates produce biofilm that is not affected by deletion of the 
ica locus responsible for PNAG production (Beenken et al, 2004), but will be degraded by 
proteolytic enzymes (O’Neill et al, 2007). Previous work has established that inactivation of 
alternative a factor a inhibited biofilm growth due to an up-regulation of the RNAIII transcript 
of agr. Further inactivation of the genes encoding Aur and the family of serine protease-like (Spl) 
proteases restored biofilm growth, indicating that these proteases have a role in the proteolytic 
dispersal of biofilms (Lauderdale et al, 2010). These inactivations, however, were largely formed 
in the SHI000 background, a robust biofilm-forming laboratory strain that work in this thesis has 
demonstrated to show minimal proteolytic activity (Fig 7), so the effect of extracellular proteases 
on the growth phenotypes of this strain is innately low. Inactivation of the agr locus in the same 
SHI 000 background produced a mutant strain that generated higher levels of biofilm, and again, 
inactivation of the Aur and Spl proteases resulted in an increase in biofilm production under 
conditions of high agr activity (Boles and Horswill, 2008). The A sigB and A agr deletions have
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been transduced into CA-MRSA USA300 (Los Angeles County Clone), where the resulting 
biofilm phenotype mirrored that of mutagenized SHI000 during flow cell biofilm growth 
(Lauderdale et al, 2009). In another work, mutation of the sarA regulatory locus, the deletion of 
which results in elevated exoprotease production, was found to decrease biofilm fomiing ability 
in an osteomyelitis isolate UAMS-1, while agr mutation in this strain had little effect on its 
biofilm forming capacity. Strain Newman, however, produced little biofilm under all conditions, 
and laboratory strain RN6390, which is defective in c B activity, did not produce a notable 
amount of biofilm unless its agr locus was deleted (Beenken et al, 2003). Together, this previous 
work indicates that the factors controlling biofilm formation vary from strain to strain despite the 
common theme of proteolytic activity leading to limited biofilm formation. It is important to note 
that the range of genes affected by these regulatory mutations is extremely broad (Beenken et al, 
2004), and little work has focussed on the biofilm-forming capacity of specific protease mutants 
not subject to broad pleiotropic effects in a model strain of clinical importance that normally 
expresses high levels of proteases. These series of proteases include those of the sspABC operon 
of S. aureus, found to be highly expressed in hypervirulent CA-MRSA USA300 and rapidly 
expressed upon phagocytic uptake (Burlak et al, 2007). This work therefore represents the first 
demonstration of a role for sspABC in regulating biofilm growth using a clinically relevant and 
highly virulent wild type strain of S', aureus.
In a popular model of biofilm growth, acidic pH is postulated to repress agr function, 
thereby inhibiting production of secreted proteins, including proteases that might otherwise 
promote biofilm dispersal (Yarwood et al, 2004). This drop in pH is the result of release of 
glucose fermentation products into the bacterial growth environment, which include acetic acid 
under aerobic growth conditions, and lactic acid during anaerobic growth (Regassa et al, 1992).
___________________________________________________________________________________________________
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Contrary to this prevailing hypothesis, this thesis has shown that glucose is necessary for optimal 
production of secreted proteases, and moreover, that production of SspA is enhanced by 
maintaining the culture at an acidic pH at which agr activity is thought to be limited. 
Immunoblotting for Hla, which is de-repressed by RNAIII translationally, supported the claim 
that agr activity is limited, since at low pH, Hla detection decreased. The fact that the same low 
pH resulted in heightened SspA production as detected by immunoblot, as well as heightened 
proteolytic activity as detected by FITC-liberation assays, strongly points to the presence of 
further layers of regulation inherent in the production of proteases, most likely in the form of an 
acid stress response system. While data in this thesis support the contention that agr activity is 
repressed at acidic pHs, a closer and more specific study of the secreted proteases positively 
regulated by this system has shown that agr repression is not the sole response to acidic 
conditions. Though this thesis has demonstrated that deletion of the proteases of the sspABC 
results in increased biofilm thickness and robustness, this increase is present at all pHs (Figure 
10), including in acidic media, where production of the proteases is classically postulated to be 
inhibited. The increase in biofilm formation in acidic conditions is therefore likely to be 
correlated to other bacterial responses than repression of proteolytic activity. These responses 
could include regulation of other biofilm associated proteins such as the S. aureus surface protein 
G (SasG) found to be involved in polysaccharide independent biofilm formation (Corrigan et al, 
2007; Tormo et al, 2007) or pH-dependent inhibition of enzymes such as nuclease that would 
otherwise degrade matrix structural components such as eDNA (Rice et al, 2007). In the course 
of the growth cycle of S. aureus, culture pH will dip and increase, and this change in pH in the 
biofilm growth phenotype may be necessary for the completion of the biofilm growth cycle,
leading to dispersal of the biofdm once pH rises enough to allow the activity of the various 
factors that contribute to dispersal aside from proteases.
In the S. aureus growth cycle, fermentation products acetate and lactate are thought to 
support a second round of bacterial growth after glucose in the growth medium is depleted, 
leading to increased pH of the culture medium after the initial dip peaking at the end of 
exponential growth (Somerville et al, 2003). The results of this thesis and a recent study by Rode 
et al, 2010 confirm a decrease in culture pH concomitant with depletion of glucose and cessation 
of exponential growth, as well as the support of further growth by lactic acid, leading to an 
increase in pH during stationary phase. However, despite a similar initial decrease and later 
increase in pH that occurs in media supplemented with acetic acid, there isdittle additional 
growth that occurs, with the presence of acetic acid severely inhibiting the final culture density at 
18 hours (Table 4). Both acetic acid and lactic acid are permeant small organic acids that can 
restrict bacterial growth by acidification of the interior of S. aureus cells (Rode et al, 2010), but 
the growth inhibition by acetic acid and not lactic acid suggests that while lactic acid is uptaken 
and metabolized by the bacteria, acetic acid is depleted from the media through other means. 
Acetic acid may be sequestered within bacterial cells or used for purposes other than metabolism, 
such as acetylation of S. aureus peptidoglycan. Increasing concentrations of acetic acid resulted 
in decreased production of SspA, most clearly seen when acetic acid supplementation was 
performed in glucose-containing, pH 5.5-buffered media that encouraged high levels of protease 
expression. This decrease of SspA may be effected directly through regulatory actions of acetic 
acid, or it may be a result of the growth-inhibitory effect indirectly altering expression patterns. 
The increase seen in SspA production as lactic acid was added to culture media suggests that 
lactic acid can be used as a carbon source to support growth. Despite the growth inhibition that
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resulted from the addition of acetic acid, these data support a role for acetic acid in biofilm 
formation. In addition to the induction of autolytic activity that releases bacterial eDNA into the 
biofilm matrix as a structural component (Rice et al, 2007), the discovery that acetic acid 
suppresses SspA production indicates that it may play a role in inhibition of biofilm dispersal in 
a protease-mediated manner.
In both microplate and plastic cover slip biofilm growth assays, biofilm growth was 
optimal at low pH, in the presence of glucose, and in the presence of a protein coat on the surface 
of either microplate well or cover slip. This protein likely provides a point of attachment for 
biofilm bacteria, and bovine serum albumin, human plasma, and bovine mucin were all effective 
at increasing biofilm formation when used to coat the attachment surfaces..The sspABCv.tc 
mutant of USA300 consistently outperformed wild type USA300 in biofilm growth, and this 
effect was abrogated by complementation of the sspABC operon in trans. In microplate wells, the 
protease-deficient mutant generated large clumps of bacteria adherent to the sides and bottom of 
the biofilm wells that were visible to the human eye before and after staining with crystal violet 
dye. Under scanning electron microscopy, the biofilm mat of USA300 sspABCv.tc was found to 
be three times as thick in cross-section as that of wild type USA300, and the large clumps of 
bacteria in the protease-deficient mutant were found to be towering communities of bacteria that 
were over twice as tall as the thickest areas of biofilm mat. The proteases of the sspABC play a 
role in dispersal of biofilm or in maintenance of an alternate composition or thickness of matrix, 
leading to decreased thickness of biofilm mat and lack of large aggregations of bacteria in 
communities in the biofilm growth phenotype of S. aureus.
In murine bacteraemia models, deletion of proteases of the sspABC operon in US A3 00, 
or deletion of these and other major proteases in historical isolate Newman, resulted in no
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significant differences in overall virulence despite possible differences in bacterial distribution 
throughout the mouse kidney that mirrors the enhanced clumping displayed by the protease-null 
mutant in vitro. This is likely attributable to a subtle role played by the proteases in the virulence 
strategy of S. aureus that is obfuscated in the complex interactions between host and pathogen 
that occur in an in vivo model. Interestingly, historical strain Newman and its derivatives 
produced higher cfu/organ counts in the infection model than emergent epidemic USA300, 
especially in the spleen and the liver. Newman is characterized by heightened .smjRS activity as a 
result of a single nucleotide polymorphism in the saeS gene, and this alters the virulence 
expression pattern of Newman such that it produces high levels of adhesion and colonization 
factors, but low levels of exotoxins and exoenzymes (Maniero et al, 2010; Novick and Jiang, 
2003). Due to its shift in colonization versus invasion factors, Newman forms large clumps or 
abscesses within the mouse organs, and this may be the cause of the increased cfu/organ count.
In terms of overall virulence, Newman did not cause more or less weight loss than USA300, so 
its change in organ load is not more pathogenic, perhaps as a result of decreased exotoxin and 
exoenzyme levels, which play a role in the triggering of an inflammatory response. When the 
sspABC mutant of USA300 was complemented in trans with pRN5548::sspABC, the 
complemented mutant showed a small but significant decrease in bacterial load in the livers of 
infected mice. This may be a result of the overexpression of proteases in conjunction with the 
high concentration of immune cells in the liver, which is meant to clean and filter blood. The 
excessive production of proteases may cause elevated levels of inflammation, leading to more 
recruitment of immune cells that would then act to clear the infection. As the major significant 
differences in vitro between wild type strains and protease-null mutants have been in the biofilm 
growth phenotype, a better in vivo model may result in elucidation of the pathophysiological
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roles of these proteases. The best model is potentially a biofilm growth model in which wild type 
and protease-null mutants are introduced to common sites of biofilm deposition, such as 
indwelling surgical devices, examples of which include catheters or stents. If the sspABC mutant 
of USA300 shows heightened biofilm growth in vivo, the infection phenotype may show 
increased virulence in the protease-null mutant, where the devices would become more readily 
colonized and blocked, leading to increased inflammatory response and morbidity on the part of 
the host animal. This and other models of biofilm growth infection represent interesting future 
directions in elucidation of the role of the proteases of the sspABC operon in infectious disease
caused by S. aureus.
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